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Multidrug resistance protein 4 (MRP4/ABCC4) is a member of the ATP-binding 
cassette transport superfamily. MRPs are able to transport structurally diverse 
conjugated organic anions including glutathione-S-conjugates and function as efflux 
pumps of therapeutic drugs and endogenous compounds. Previous studies had shown 
that the substrates of MRP4 include methotrexate, cAMP and cGMP, metabolites of 
chemotherapeutic agents, glutathione-conjugated and glucuronide-conjugated organic 
anions.  
 
Like MRP1-3, MRP4 can also perform the transport of glutathione-S-conjugates 
despite the differences in the membrane topology and drug resistance profiles 
between MRP4 and MRP1-3. MRP4 has only two transmembrane domains and two 
ATP-binding domains with the absence of a third (N-terminal) membrane spanning 
domain, which is present in MRP1-3. Using cells stably overexpressing MRP4, this 
study confirmed that MRP4 can indeed facilitate the efflux of the glutathione 
conjugate, bimane-glutathione. The efflux increased with time and > 72% of the 
conjugate was exported after 20 minutes. A concentration-dependent inhibition of 
bimane-glutathione efflux was observed with some common dietary plant 
polyphenols including ellagic acid, curcumin, apigenin, luteolin and kaempferol.  In 
addition, MRP4 can facilitate the efflux of glutathione directly and the concentration-
dependent inhibition of glutathione efflux was also observed with these plant 
polyphenols including ellagic acid, curcumin, apigenin, kaempferol, luteolin, 
genistein and quercetin. 
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As a step toward determining the substrate-binding sites of MRP4, site-directed 
mutagenesis of highly conserved residues were carried out on the basis of the 
alignment of the protein sequences of MRP family. We replaced three highly 
conserved charged amino acids Arg165, Arg951 and Asp953 with conserved or non-
conserved substitution. The single-nucleotide polymorphism (SNP) site Cys171Gly in 
the transmembrane domain of MRP4 was also examined. All mutant clones were 
transfected into human Hep G2 cells and the localization and the expression levels of 
mutant MRP4 were comparable to that of wild-type MRP4. Our finding shows that 
both R165N and C171G mutants lost their ability to confer resistance to purine 
analogues 6-TG and 6-MP and to transport glutathione-S-conjugates (bimane-GS). 
Only the R165N mutant is unable to transport glutathione. In brief, our present study 
indicates that highly conserved charged amino acids Arg165 and the SNP site 
Cys171Gly in the transmembrane domains of MRP4 are important determinants for 
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1.    Introduction 
 1.1.    Transporters 
 
Transporter-mediated processes play key roles in the absorption, distribution and 
excretion (ADE) of many endogenous and xenobiotic compounds. Drugs ingested 
into the body are transported through the plasma membrane several times. Most drugs 
need transporters for their trans-membrane transport. These transporters are classified 
into five groups by their difference in molecular structures, substrate specificities and 
transport mechanisms. They are organic ion transporter superfamily, ATP-dependent 
transporter superfamily, peptide transporter family, organic anion transporting 
polypeptide family and amino acid-polyamine-choline transporter superfamily (Endou, 
2000). The disposition of endogenous compounds, drugs and other xenobiotics are 
performed by transporters in many organs. In the intestine, liver, kidney and brain, 
transporters are important in the absorption, distribution and excretion of therapeutic 
drugs. In the liver, transporters are involved in the uptake of drugs from blood to liver, 
across the sinusoidal membrane and hepatobiliary distribution and excretion of drugs 
and metabolites (Kim, 2000; Ayrton and Morgan, 2001). In the kidney, transporters at 
the basolateral and luminal membranes are involved in renal secretion of drugs (Inui 
et al., 2000; Ayrton and Morgan, 2001). In the intestine and brain, transporters, such 
as P-glycoprotein, play a significant role in the extrusion of drugs from these organs 
so that the drug absorption and brain penetration are attenuated (Suzuki and Sugiyama, 
2000; Ayrton and Morgan, 2001). Drug efflux transporters, such as multi-drug 
resistance protein 1 and 2 (MPR1 and MRP2), and the uptake transporters, such as 
members of the organic anion-transporting polypeptides (OATPs) and organic anion 
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transporter families (OATs), can mediate the cellular efflux and uptake of a large 
number of structurally divergent compounds, respectively, especially in organs such 
as the intestine, liver and kidney (Marzolini et al., 2004).  
 
Drug absorption mainly happens in the gastrointestinal tract. The intestine, primarily 
regarded as an absorptive organ, is also able to eliminate certain organic acids. The 
interactions of drugs with intestinal membrane transporters have an important impact 
on the intestinal drug absorption and secretion (Kunta and Sinko, 2004). Some 
transporters are involved in the active absorptive influx of compounds from the lumen 
into the portal bloodstream (Tsuji and Tamai, 1996). Conversely, other transporters 
are responsible for the active efflux of drugs and xenobiotics from gut epithelial cells 
back into the lumen. Transporters present in the gut epithelial plasma membrane 
include members of a number of transport protein families such as MDR, MRP, 
OATP, OCT and OAT (Ayrton and Morgan, 2001). Certain organic solutes, such as 
amino acid-mimetic drugs, monocarboxylic acid drugs, phosphonic acid drugs, bile 
acids, are thought to be absorbed from the gastrointestinal tract through transporter-
mediated mechanisms. By contrast, absorption of many lipophilic drugs is limited by 
Pgp or other ATP-dependent active secretory mechanisms at the brush border 
membranes of intestinal epithelial cells (Sai and Tsuji, 2004). For example, P-
glycoprotein (MDR1), a member of MDR, is present on the villus tip of the apical 
brush border membrane of gut enterocytes and is orientated to pump substrates from 
inside the cells back into the lumen of the intestine (Wagner et al., 2001).  
 
The hepatobiliary system and the kidneys are the main routes by which drugs and 
their metabolites leave the body (van Montfoort et al., 2003). The liver plays a key 
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role in the clearance and excretion of many drugs and hepatobiliary excretion of drugs 
involves passage from blood, through the hepatocyte, and into the bile. Many 
transporters are present on the canalicular membrane to mediate this process. The 
OATPs, which have been shown to be specifically located on the liver sinusoidal 
membrane in rodents and humans, are mainly responsible for the hepatic uptake of 
large amphipathic organic anions, organic cations and uncharged substrates, whereas 
OCTs and OATs mediated the uptake of predominantly small organic cations and 
anions in liver (van Montfoort et al., 2004; Ayrton and Morgan, 2001). Members of 
ATP-binding cassette family of transporters are mainly involved in the active drug 
secretion into bile. These transporters include P-glycoprotein encoded by multidrug-
resistance gene (MDR), the bile salt export pump (BSEP) and a distinct ATP-
dependent transport system referred to as cMOAT or MRP2 (Ayrton and Morgan, 
2001). The kidney plays an important role in the elimination of many drugs which 
include active tubular secretion in renal clearance. It has been demonstrated that an 
increasing number of transporter families, such as OAT, OCT, OATP, MDR and 
MRP, are present in the kidney. The first step in drug elimination in kidney is uptake 
into proximal tubular cells, which is mainly mediated by OCTs and OATs. Various 
transporters mediate the active secretion of drugs, and hydrophilic cations and anions 
in the renal tubule (van Montfoort et al., 2004; Ayrton and Morgan, 2001).  
 
 
   
 17
1.2.   ABC transporter 
To date, more than fifty human ATP-binding cassette (ABC) genes have been 
identified. High sequence homology in the nucleotide binding domains (NBDs) 
allows identification and classification of members of the ABC transporter family. 
The functional protein usually is comprised of two NBDs and two transmembrane 
domains (TMDs). There are seven subfamilies, ABCA through ABCG. These are 
expressed in both normal and malignant cells. They are involved in the transport of 
many substances, including the excretion of toxins from the liver, kidneys, and 
gastrointestinal tract, and they limit permeation of toxins to vital structures, such as 
the brain, placenta, and testis. Mutations in the genes encoding these transporter 
proteins can induce a multitude of defects, presenting as autosomal recessive 
conditions (Leonard et al., 2003).  
 
The ABC superfamily is one of the largest protein superfamilies and contributes to the 
active transport of a wide variety of compounds across biological membranes (Klein 
et al., 1999). Most ABC proteins are membrane transporters, which can translocate 
various substrates to various compartments. There are four types of transporters on 
the cell membrane: ion channel, passive transporter, primary active transporter and 
secondary active transporter. ABC proteins belong to the primary active transporter 
category (Figure 1.1).  











Figure 1.1   Classification of the types of transporters. 
 
ABC protein family is divided into four subfamilies: MRP/CFTR (ABCC, to-date: 
thirteen members), MDR/TAP (ABCB, eleven members), ALD (ABCD, four 
members) and ABC1 (ABCA, twelve members) and three smaller groups: white 
(ABCG, six members), GCN20 (ABCF, three members) and the subgroup OABP 
(ABCE) with only one ‘single member’. A large number of the known ABC proteins 
are active pumps (Borst et al., 1999; Cole and Deeley, 1998; Hipfner et al., 1999; 
Higgins, 1992; Klein et al., 1999). 
 
As membrane transporters, the typical eukaryotic ABC protein contains four domains. 
These include two hydrophobic, polytopic transmembrane domains (TMDs), also 
called membrane spanning domains (MSDs), and two hydrophilic, cytosolic 
nucleotide binding domains (NBDs). They are organized in pairs (TMD-NBD or 
NBD-TMD) and expressed either as one continuous unit or two separate polypeptides 
(Decottignies and Goffeau, 1997; Hipfner et al., 1999). In most ABC transporters, the 
binding and subsequent hydrolysis of ATP at their NBDs provide energy for 
transporting substrates across the membrane. The substrates include phospholipids, 
ions, organic anions, amino acids, peptides, steroids, drugs and other xenobiotics.  
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      1.3.    MRP family 
MRPs are the members of the ATP binding cassette (ABC) superfamily of transport 
proteins. MRPs are multispecific organic anion transporters, which can transport 
negatively charged anionic molecules and neutral molecules conjugated to glutathione, 
glucuronate or sulfate. The MRP family comprises nine related ABC transporters that 
are able to transport structurally diverse lipophilic anions and function as efflux 
pumps of therapeutic drugs and endogenous compounds (Kruh et al., 2003).  
 
The amino acid sequence of MRP1 resembles P-glycoprotein encoded by human 
MDR1 gene only to a modest extent (about 15%), and its structure is distinct as well. 
MDR1, a member of the MDR/TAP subfamily, is the most extensively studied 
transporter involved in multidrug resistance. The P-glycoprotein (MDR1) was the first 
cloned human ABC protein (Roninson et al., 1986). It is located on the apical (or 
luminal) surface of polarized epithelial cells. It is found at the pharmacological barrier 
of the body and present on the brush border membrane of intestinal cell, on the biliary 
canalicular membrane of hepatocytes, as well as on the luminal membrane in 
proximal tubules of kidney (Bosch et al., 1996). The MDR1 transporter can extrude a 
wide range of structurally unrelated hydrophobic toxic compounds. It is suggestive 
that the physiological function of MDR1 is to protect cells against toxic compounds. 
MDR1 is also expressed in tumor cells. At some stages of treatment with natural 
product drugs, the expression level of MDR1 increases by 50% in all human tumors. 
The failure of some tumors to respond to therapy is clearly related to the increase in 
Pgp. Therefore, increased Pgp activity in tumor cells can lower the concentration of 
cellular chemotherapeutic agents and this results in anti-cancer drug resistance. 
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However, the multidrug resistance mediated by MDR1 is not the only single factor in 
the therapeutic outcome in human malignancies (Bosch et al., 1996). Experimental 
studies in vitro also showed that Pgp is not the only cause of MDR. Many cells 
selected for resistance do not contain increased levels of Pgp but nevertheless are 
resistant to a broad range of natural product drugs. Several of these cell lines contain 
raised levels of a second member of the ABC transporter proteins, the MDR-
associated protein (MRP), which was discovered by Cole et al. (Cole et al., 1992). 
  
The drug resistance phenotype of MRP protein overlaps with that of Pgp. It is 
associated with resistance to anthracyclines, etoposide, and vinca alkaloids. However, 
the spectrum of drug resistance of MRP and Pgp is not exactly the same. MRP does 
not confer resistance to taxol, which is a clinically important agent and a part of the 
Pgp resistance profile. Moreover, Pgp-mediated multidrug resistance is readily 
reversed by verapamil and cyclosporin A (analogues), but that mediated by MRP is 
not.  
 
The MRP subfamily of ABC transporters from mammals consists of nine members, 
six of which have been implicated in the transport of amphipathic anions. Based on 
the structure, MRP1, MRP2, MRP3, MRP6 and MRP7 are termed as ‘long’ MPRs 
because of an additional MSD0 at the N-terminal, while MRP4, MRP5, MRP8 and 
MRP9 are ‘short’ MRPs (Figure 1.2). In polarized epithelial cells, MRP1, MRP3, 
MRP5 and MRP6 are localized on the basolateral membranes. MRP2 is localized on 
the apical membranes. MRP4 is localized on the basolateral membranes in human 
prostatic glandular cells and on the apical membranes in rat kidney tubule cells. The 
localizations of MRP7, MRP8 and MRP9 have not been determined (Figure 1.3).  
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Figure 1.2   Topology of MRP family members. (a). Schematic depicting the 
organization of protein domains. Stripes, membrane spanning domain; open, 
cytoplasmic loops located between MSD0 and MSD1, NBF1 and MSD2 and at the C-
terminus; black, nucleotide binding folds. (b). Topological model of MRP1 (which 
resembles MRP2, MRP3, MRP6 and MRP7) (top) and MRP4 (which resembles 




Figure 1.3   Subcellular localization of MRPs in polarized epithelial cell 
surrounding a hypothetical lumen (Kruh et al., 2003). 
 
The structures of MRP1, MRP2, and MRP3 are very similar. They confer resistance 
to a variety of natural products as well as methotrexate, and have the facility for 
transporting glutathione and glucuronate conjugates. MRP1 is a ubiquitously 
expressed efflux pump for the products of phase II xenobiotic detoxification. It is also 
involved in immune responses involving cysteine leukotrienes. MRP2, whose 
hereditary deficiency results in Dubin-Johnson syndrome, functions to extrude 
organic anions into the bile. MRP3 is distinguished by its capacity to transport 
glycocholate, a monoanionic bile constituent, and may function as a basolateral back-
up system for the detoxification of hepatocytes when the usual canalicular route is 
impaired by cholestatic conditions. MRP4 and MRP5 resemble each other more 
closely than they resemble MRPs 1-3 and confer resistance to purine and nucleotide 
analogs which are either inherently anionic, as in the case of the anti-AIDS drug 
PMEA, or are phosphorylated and converted to anionic amphiphiles in the cell, as in 
the case of 6-MP. Given their capacity for transporting cyclic nucleotides, MRP4 and 
MRP5 have also been implicated in a broad range of cellular signaling processes 
involving cyclic GMP and cyclic AMP. The drug resistance activity and physiological 
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substrates of MRP6 are unknown. However, its hereditary deficiency results in 
pseudoxanthoma elasticum, a multisystem disorder affecting skin, eyes, and blood 
vessels. Hence, MRP6 may play a role in elastic tissue homeostasis. The 
physiological functions of MRP7, MRP8 and MRP9 are still unknown.  Some MRPs 
can also transport neutral drugs if co-transported with glutathione. It is hoped that 
elucidation of the resistance profiles and physiological functions of the different 
members of the MRP subfamily will provide new insights into the molecular basis of 
clinical drug resistance (Kruh and Belinsky, 2003; Hopper et al., 2001; Borst et al., 
1999).  
          1.3.1.     The role of MRPs in detoxification  
Metabolism of toxicants 
Lipophilic xenobiotics and endogeneous compounds are often metabolized before 
being eliminated from the cell. The metabolism of these compounds can be grouped 
into either phase I or phase II reactions. 
In phase I, a function polar group including a hydroxyl, carboxyl, amino or thio group, 
is introduced to the compounds. In phase II, the phase I metabolite is conjugated with 
various endogenous substrates, such as sugars, amino acids, glutathione (GSH) and 
sulfate, to form water soluble products that are readily excreted (Hodgson et al., 1998). 
An important phase II reaction is the reaction catalyzed by glutathione-S-transferases. 
Glutathione-S-transferases are anionic in nature and are transported out of cells 
through an ATP-dependent process. A key feature of MRP proteins is the ability to 
transport glutathione-S-conjugates.  
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GSH related transport 
Glutathione (GSH), γ-Glu-Cys-Gly is a tripeptide, and is present in all cells at high 
levels. GSH has many important roles in the protection of cells from oxidative stress. 
It is responsible for the removal of toxic peroxides that form in the course of growth 
and metabolism under aerobic conditions. The ratio of reduced GSH to the oxidized 
form, glutathione disulphide (GSSG), is a reflection of cellular redox status. 
Maintenance of low cellular GSSG concentrations and high GSH level is important 
for cellular homeostasis. Some MRP proteins, MRP1 and MRP2, may be important in 
maintaining cellular redox status as they can transport both GSH and GSSG.  
Aiding detoxification is another important function of GSH. A variety of electrophilic 
compounds, including anticancer drugs, such as chlorambucil and melphalan, can be 
conjugated to GSH by glutathione S-transferase (GST) and are then transported out of 
the cell by MRPs (Klein et al., 1999; Borst et al., 2000).  
Glutathione conjugation reaction results in the removal of reactive electrophiles. This 
helps to protect vital nucleophilic groups in macromolecules, such as proteins and 
nucleic acids. The resulting glutathione-conjugate is further metabolized through a 
series of reactions and finally into mercapturic acids that can be excreted either in the 
bile or in the urine (Hodgson et al., 1997). 
In other instances, GSH is not conjugated to compounds but is co-transported with the 
drugs by MRP. In both cases, a constant supply of GSH is required (Figure 1.4). 
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Figure 1.4   Model showing interrelation between multidrug resistance-associated 
protein (MRP) and glutathione (GSH). MRP1 transports oxidized glutathione (GSSG) 
at a relatively high concentration. Reduced GSH is transported out of the cell with 
very low affinity. However, some xenobiotics, such as the flavone apigenin and the 
calcium channel blocker verapamil, can be conjugated to GSH by glutathione S-
transferase (GST) and then transported by MRP; others are co-transported with GSH. 
In both cases, drug transport is dependent on the continue supply of GSH (Leslie et al., 
2001a).  
 
Elimination of xenobiotics by MRPs 
MRP proteins are amphipathic anion transporters that can transport uncharged, 
anionic or mildly cationic anticancer agents. Considering the structurally diverse 
substrates transported by MRP proteins, it is complex to decipher the mechanism. The 
current efflux model is that MRP1 contain a bipartite or multipartite binding site. One 
side of the structure can bind to the hydrophobic or anionic conjugated compounds or 
similarly to the unconjugated substrates while the other to GSH. Unconjugated 
compounds may be co-transported with free GSH rather than converted into anions 
inside of the cells (Loe et al., 1996a; Borst et al., 1999) 
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         1.3.2.    MRP1 
The 190-kDa multidrug resistance protein 1 (MRP1) is a member of the branch of the 
ATP-binding cassette (ABC) superfamily of transport proteins designated ABCC. 
When overexpressed in tumor cells, MRP1 confers resistance to anticancer drugs and 
other xenobiotics with remarkably diverse structures and charges. MRP1 is also a 
primary active transporter of conjugated organic anions that include GSH-, 
glucuronide-, and sulfate-conjugated derivatives of both endo- and xenobiotics, 
suggesting a role for MRP1 in the disposition and elimination of these compounds 
(Hipfer et al., 1999).  
At the time of the molecular identification of MRP1, its modest degree of sequence 
similarity with Pgp was striking in view of the overlap in their resistance profiles. 
From studies using MRP-transfected cell lines, MRP1 is able to confer resistance to 
anthracyclines, vinca alkaloids, epipodophyllotoxins, camptothecins and methotrexate, 
but not to taxanes, which are important components of the Pgp profile (Zaman et al., 
1994). Numerous reports document the expression of MRP1 in cancers that are 
treated with anthracyclines, camptothecins and etoposide, such as leukemia and breast, 
colorectal and germ cell, respectively, and in some cases, the correlations between 
clinical outcome and expression have been drawn (Leslie et al., 2001; Hooijberg et al., 
1999a). It is reasonable to infer that MRP1 contributes to the inherent sensitivity of 
cancers in which it is expressed.  
In spite of the similarity in the resistance profiles of Pgp and MRP1, the substrate 
selectivities of the pumps differ markedly. The substrates of Pgp are neutral or mildly 
positive lipophilic anions, while the substrates of MRP1 include structurally diverse 
glutathione, glucuronate and sulfate conjugates, such as the cystein leukotriene LTC4, 
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the estrogen glucuronide estradiol-17-β-D-glucuronide (E217βG) and sulfated bile 
acids (Leier et al., 1994; Jedlitschky et al., 1996; Loe et al., 1996a).  Glutathione 
conjugates and glucuronate conjugates have been used in characterizations of MRP1 
because they represent the products of phase ΙΙ of cellular detoxification of 
hydrophobic xenobiotics. Efflux pumps involved in their cellular extrusion (phase Ш), 
which have been previously referred to as GS-X pumps in the case of glutathione 
conjugates, had also been biochemically characterized in many cell types (Ishikawa, 
1992). MPR1 is now shown to be a ubiquitous GS-X pump; able to transport 
glutathione conjugates, and is expressed in many tissues (Kruh et al., 1995; Flens et 
al., 1996). 
In the structural studies of MRP1, the topology of the N-terminal extension of MRP1 
(MSD0 and L0), a striking structural feature of this pump, has been determined (Bakos 
et al., 1996; Hipfner et al., 1997; Kast and Gros, 1997). The MSD0 domain is 
dispensable for the transport functions (Figure 1.2), because an N-terminal truncated 
mutant that lacks this domain is functional with respect to membrane vesicle transport 
activity, susceptibility to vanadate-induced nucleotide trapping, able to assume 
localization in polarized cells and mediating cellular efflux of daunorubicin and 
glutathione conjugates (Bakos et al., 1998). However, extending the N-terminal 
truncation to include the L0 domain abrogates the activity of the pump, indicating that 
L0 domain is essential for the function. Studies also show that MRP1 activity can be 
affected by point mutations in the extracellular portion of the N-terminus and in 
MSD0.  It has been explored by using photoaffinity labeling the drug binding sites on 
MRP1 in MSD1 and MSD2, especially TM10-11 in MSD1 and TM16-17 in MSD2. 
The results of site-directed mutagenesis studies also support the involvement of these 
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transmembrane (TM) helices in MRP1 activity (Ito et al., 2001; Zhang et al., 2002; 
Haimeur et al., 2002; Ren et al., 2002).  
MRP1 is a basolateral transporter whose operation results in the movement of 
compounds away from luminal surfaces and into tissues that lie beneath the basement 
membrane (Evers et al., 1996). For MRP1-mediated efflux, glutathione plays an 
important role (Figure 1.5).  
   
  
Figure 1.5   Involvement of glutathione in MRP1-mediated transport (Kruh et al., 
2003). 
 
Some compounds can be effluxed by MRP1 after conjugated with reduced glutathione 
(Figure 1.5a). Some agents, such as vinca alkaloids and anthracyclines are not 
conjugated with glutathione but are cotransported with GSH (Figure 1.5b). Certain 
anionic conjugates such as estrone-3 sulfate are also dependent on glutathione in 
MRP1-mediated efflux. But this transport dose not appear to be associated with the 
forming of glutathione conjugates or cotransport with glutathione. The transport is 
just enhanced by glutathione (Figure 1.5c). Some compounds, such as the Pgp 
inhibitor verapamil, and certain bioflavonoids, are able to stimulate the transport of 
glutathione by MRP1, but are not transported themselves (Loe et al., 2000; Leslie et 
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al., 2003). So these compounds exert an effect that increases the affinity of the pump 
for glutathione (Figure 1.5d). In addition, GSSG, the oxidation product of glutathione, 
is a substrate of MRP1 (Figure 1.5e) (Leier et al., 1996).  The involvement of MRP1 
in this process is supported by experiments showing that MRP1 inhibitors diminish 
cellular extrusion of GSSG in rat astrocyte cells in which the pump is endogenously 
expressed (Hirrlinger et al., 2001).     
MRP1 is thus a glutathione and glucuronate conjugate pump and it also contributes to 
the resistance for anthracyclines, epipodophyllotoxins, vinca alkaloids and 
camptothecins. The physiological roles for MRP1 include protecting certain tissues 
from the effects of chemotherapeutic agents, and in inflammation and dendritic cell 
function (Kruh et al., 2003).  
         1.3.3.      MRP2 
MRP2 is a lower affinity transporter for conjugates and can mediate transport of 
compounds such as E217βG. The substrate selectivity of MRP2 is similar to that of 
MRP1 with respect to glutathione and glucuronate conjugates, but the transport 
characteristics of the pumps differ in detail (Cui et al., 1999). In spite of the similarity 
in substrate range, the functions of MRP2 are distinct from those of MRP1 because of 
the differences in expression pattern and subcellular polarity. MRP2 has an apical 
localization in polarized cells. It is mainly expressed in liver canaliculi (Kartenbeck et 
al., 1996). 
In earlier studies, MRP2 was often referred to as the canalicular multispecific organic 
anion transporter (cMOAT), which aptly describes its ability to extrude a range of 
lipophilic anions into the bile.  
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The drug resistance profile of MRP2 is similar to that of MRP1 with respect to 
anthracyclines, vinca alkaloids, epipodophyllotoxins and camptothecins (Koike et al., 
1997; Cui et al., 1999). Glutathione also plays a role in MRP2-mediated transport of 
hydrophobic anticancer agents. However, an obvious difference between MRP1 and 
MRP2 is that MRP2 is able to confer resistance to cisplatin, an agent that is known to 
form toxic glutathione conjugates in the cell (Ishikawa and Aliosman, 1993).  
Dubin-Johnson syndrome of the human is a largely asymptomatic disorder whose 
principal manifestation is jaundice. This abnormality reflects the role of MRP2 in the 
biliary excretion of bilirubin glucuronide from hepatocytes into bile (Konig et al., 
1999). 
         1.3.4.      MRP3 
Among MRP family members, MRP3 has the highest degree of amino acid homology 
resemblance to MPR1 (58%). Its substrate selectivity overlaps with that of MRP1 and 
MRP2 with respect to the transport of glutathione and glucuronate conjugates 
(Hirohashi et al., 1999; Zeng et al., 1999). However, the affinity of MRP3 for 
conjugates is significantly lower than that of MRP1, and its drug resistance abilities 
are not as extensive as either MRP1 or MRP2. Various studies also indicate that 
MRP3 is probably only able to confer low levels of resistance to etoposide and 
teniposide (Kool et al., 1999; Zeng et al., 1999; Zelcer et al., 2001). In contrast to 
MRP1 and MRP2, MRP3 does not require glutathione for mediating the transport of 
natural products (Zelcer et al., 2001). 
 
MRP3 is usually expressed at low levels at the basolateral surfaces of bile duct cells 
and hepatocytes and is induced during cholestatic conditions (Hirohashi et al., 1998; 
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Donner and Keppler, 2001; Soroka et al., 2001). MRP3 is able to transport 
monoanionic bile acids such as glycocholate and taurocholate, which are significant 
components of bile acids in humans and rodents (Hirohashi et al., 2000; Zeng et al., 
2000). These features suggest that MRP3 may function to detoxify hepatocytes of bile 
acids and other conjugates by mediating the extrusion of these compounds into 
sinusoidal blood when the usual canalicular route of excretion is blocked (Gerloff et 
al., 1998; Bodo et al., 2003).  
 
It has also been speculated that MRP3 may be involved in the enterohepatic 
circulation of bile acids (Rost et al., 2002). In addition to gut and liver, MRP3 is 
expressed in a variety of other tissues, including pancreas, kidney, adrenal and 
gallbladder (Belinsky et al., 1998; Kiuchi et al., 1998). 
 
         1.3.5.      MRP4 
Multidrug resistance protein 4 (MRP4/ABCC4) was originally designated as MOAT-
B. Its distribution in human tissues and its localization to chromosome 13 was first 
reported in 1997 (Kool et al., 1997). In 1998, the 5.9kb MRP4 cDNA was 
successfully isolated. It encodes an open reading frame of 1,325 amino acids. 
Subsequently, the localization of the MRP4 gene on 13q32 was also identified (Lee et 
al., 1998, 2000). 
 
MRP4 is widely expressed in human tissues, including liver, intestine, prostate, lung, 
muscle, brain, pancreas, testis, ovary, adrenal gland, bladder and gallbladder (Rius et 
al., 2003; Lee et al., 1998, 2000). It was shown that MRP4 is localized in basolateral 
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membranes and the basolateral cytoplasm region of basal cells by immunostaining on 
prostate tissue (Lee et al., 2000). Recently, human MRP4 has been shown localized to 
the apical membrane of the proximal tubule in the kidney (Smeets et al., 2004). In the 
hepatocytes, MRP4 is localized mainly in the basolateral membrane (Rius et al., 
2003). 
 
Like MRP1 and MRP2, MRP4 can mediate the efflux of gluthathione conjugates and 
glucuronate conjugates. However, MRP4 do not confer resistance against 
anthracyclines, vinca alkaloids or epipodophyllotoxins (Lee et al., 2000; Chen et al., 
2001, 2002). Instead, MRP4 mediates resistance to purine analogues and other 
nucleoside-based antiviral drugs (Schuetz et al., 1999; Lee et al., 2000) such as the 
antiviral compound 9-(2-phosphonylmethoxyethyl) adenine (PMEA). MRP4 also 
catalyzes the MgATP-energized transport of cGMP and cAMP (Jedlitschky et al., 
2000; Chen et al., 2001). This distinct property might be due to the absence of a third 
(N-terminal) membrane spanning domain (Belinsky et al., 1998), which is present in 
MRP1-3.  Analysis of transfected cell lines further revealed that MRP4 is not only 
able to confer resistance to the cyclic nucleotide analogs employed in the treatment of 
hepatitis B, but is also a resistance factor for anticancer agents such as 6-
mercaptopurine (6MP) and 6-thioguanine (TG), methotrexate and the antiviral 
ganciclovir (Lee et al., 2000; Chen et al., 2001; Adachi et al., 2002).  Both 6MP and 
6TG are anticancer purine analogs with sulfur at the C-6 position, which are 
converted in the cell to nucleotide analogs. MRP4 is also able to transport a model 
steroid conjugate substrate, glucuronide E217βG. Bile salts, especially sulphated 
derivatives, and cholestatic oestrogens inhibited the transport of E217βG mediated by 
MRP4, such as oestradiol 3, 17-disulphate and taurolithocholate 3-sulphate. This 
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suggests that these compounds are MRP4 substrates. Moreover, MRP4 can transport 
dehydroepiandrosterone 3-sulphate (DHEAS), which is the most abundant circulating 
steroid in humans (Zelcer et al., 2003). By using the inside-out membrane vesicles, it 
was reported that MRP4 can transport prostaglandin E1 (PGE1) and PGE2 (Reid et al., 
2003). In addition, glutathione is also a possible substrate of MRP4, and decreased 
intracellular glutathione level in MRP4-transfected cells have been reported 
(Wijnholds et al., 2000; Lai and Tan, 2002).  
 
GSH is an important endogenous antioxidant. In the liver, most of the GSH is released 
across the hepatocyte sinusoidal (basolateral) membrane into the blood circulation 
(Kaplowitz et al., 1985). Previous studies have demonstrated that MRP4 is localized 
to the basolateral membrane of human hepatocytes and human hepatoma Hep G2 cells 
and can mediate the release of GSH into the extracellular space (Rius et al., 2003; Lai 
and Tan, 2002). Furthermore, MRP4 can function as an ATP-dependent cotransporter 
of GSH together with monoanionic bile salts, such as cholyltaurine, cholylglycine and 
cholate. Hence, it may function as an overflow pathway during impaired bile salt 
secretion across the canalicular membrane into bile (Rius et al., 2003).  
 
MRP4 mRNA is also expressed in the intestinal tract, including duodenum, jejunum 
and ileum (Prime-Chapman et al., 2004; Zimmermann et al., 2004). It is suggested 
that MRP4 may play a role in intestinal drug efflux (Taipalensuu et al., 2001), and it 
was demonstrated that basolateral MRP4-mediated calcein efflux from human 
intestinal epithelial Caco-2 cells is gluthathione-dependent and this calcein efflux was 
inhibited by MRP4 inhibitors, such as MK571 and diclofenac (Prime-Chapman et al., 
2004). The expression of MRP4 was shown to be inducible by azidothymidine 
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(Jorajuria et al., 2004). In addition, increased MRP4 expression was also observed in 
farnesyl/bile acid receptor (FXR/BAR) nullizygous mice after cholic acid feeding 
(Schuetz et al., 2001). 
  
The proximal part of the kidney nephron plays an important role in the renal excretion 
of organic anions. The cells of the proximal tubule are equipped with various 
transport systems for uptake of organic anions from blood across the basolateral 
membrane and subsequent excretion across the apical (brush border) membrane into 
the urine. p-Aminohippurate (PAH) is the classical substrate used in the 
characterization of organic anion transport in renal proximal tubule cells. Earlier 
studies have been shown that the multidrug resistance protein 2 (MRP2) is localized 
to the apical side of proximal tubules in the kidney and can mediate ATP-dependent 
PAH transport (Schaub et al., 1997). Recently, expression of MRP4 mRNA is also 
detected on the apical side of renal proximal tubules (van Aubel et al., 2002). Present 
studies showed that renal cortical expression of MRP4 was approximately five fold 
higher as compared with MRP2 by realtime PCR and western blot analysis and MRP4 
was a novel PAH transporter with higher affinity. Studies also showed that various 
inhibitors of MRP2-mediated PAH transport also inhibited MRP4, such as probenecid. 
It is suggested that MRP4 is important in renal PAH excretion (Smeets et al., 2004). 
MRP4 can mediate probenecid-sensitive ATP-dependent transport of MTX, E217βG, 
cAMP and cGMP in the kidney. It can also mediate cellular drug resistance to many 
antiviral drugs, including adefovir, PMEG and AZT. Thus, it is possible that MRP4-
mediated excretion of these antiviral drugs contributes, in part, to the nephrotoxicity 
associated with certain antiviral drugs (Lee and Kim, 2004).  
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Present studies show the expression of MRP4 mRNA in human brain by using 
quantitative PCR analysis. The MRP4 protein was detected on the luminal side of 
brain capillary endothelial cells as well as the astrocytes of the subcortical white 
matter. Thus, it may contribute to the cellular efflux of endogenous anionic 
gluthathione or glucuronate conjugates, cyclic nucleotides and gluthathione. It may 
play an important role in conferring resistance to some cytotoxic and antiviral drugs 
in the brain (Nies et al., 2004). This was confirmed by the fact that in Mrp4-deficient 
mice, there was increased accumulation of topotecan, an Mrp-4 substrate, in brain 
tissue and cerebrospinal fluid, indicating that MRP4 does indeed play a role in 
protecting the brain from cytotoxins (Leggas et al., 2004). 
 
         1.3.6.      MRP5 
A series of different size transcripts can be generated from the MRP5 gene. At least 
four mRNAs of MRP5 have been detected. They are approximately 10 kb, 6.0 kb, 5.5 
kb, and 1.6 kb (Suzuki et al., 2000). MRP5 is mainly expressed at high transcript level 
in skeletal muscle, brain, and heart, and at a very low level in liver (McAleer et al., 
1999).  
 
Within the MRP subfamily, MRP4, MRP5, MRP8 and MRP9 are unique. All lack the 
TMD0 domain present in MRP1, MRP2, and MRP3 but retain the L0 linker (Klein et 
al., 1999). MRP5 is also an organic transporter (McAleer et al., 1998). Like MRP4, 
MRP5 also does not confer resistance against anthracyclines, vinca alkaloids or 
epipodophyllotoxins. This protein also acts as the cellular export of cyclic nucleotides 
and confers resistance to thiopurine anticancer drugs such as 6-MP and thioguanine, 
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and the anti-HIV drug PMEA (Schuetz et al., 1999; Lee et al., 2000; Wijnholds et al., 
2000). Studies showed that MRP5 functions as an ATP-dependent export pump for 
cAMP and cGMP (Jedlitschky et al., 2000). Thus, MRP5 is also a nucleotide 
analogue pump. However, the export system for cAMP is not as efficient as for cGMP. 
It was observed that the efficiency of MRP5-mediated transport of cAMP is more 
than 20-fold lower than that for cGMP. In isolated membrane vesicles, a significant 
MRP5-mediated transport of MRP1 and MRP2 substrates leukotriene C4, 17β-
glucuronosyl estradiol, and glutathione disulfide could not be detected (Jedlitschky et 
al., 2000).    
 
       1.3.7.      MRP6 
MRP6 is able to transport lipophilic anions. It is localized in basolateral membranes. 
Human MRP6 was shown to transport glutathione conjugates such as LTC4 and N-
ethylmaleimide-glutathione, but not glucuronate conjugates such as E217βG (Belinsky 
et al., 2002; Ilias et al., 2002). These studies have revealed that MRP6 is an 
amphipathic anion transporter.  
 
Analysis of MRP6-transfected CHO cells indicated that MRP6 is able to function as a 
drug pump (Belinsky et al., 2002). This study showed that MRP6 is able to confer low 
levels of resistance to etoposide and teniposide, but not to podophyllotoxin. In 
addition, low levels of resistance were detected for anthracyclines and cisplatin (Kruh 
and Belinsky, 2003).  
 
 37
Mutations in MRP6 were determined to be the genetic basis of Pseudoxanthoma 
elasticum (PXE), a heritable connective tissue disorder that affects elastic tissues in 
the body. The primary sites of this disease are the skin, eyes, and cardiovascular 
system. The corresponding clinical manifestations are the redundant sagging skin, 
visual impairment, intermittent claudication, blood vessel rupture and myocardial 
infarction. Although the involvement of MRP6 mutations in PXE has been 
demonstrated, little is known about the pathophysiological mechanism of MRP6 
deficiency in PXE (Belinsky et al., 2002). 
        1.3.8.      MRP7 
On the basis of amino acid sequence comparisons, MRP7 is a member of the C branch 
of ABC transporter (Hopper et al., 2001), a family of proteins that includes both 
lipophilic anion pumps and regulators of ion channels. The MRP7 cDNA sequence 
encodes a 1492 amino acid ABC transporter whose structural architecture resembles 
that of MRP1, MRP2, MRP3, and MRP6 and whose transmembrane helices are 
arranged in three membrane spanning domains. However, in contrast to the latter 
transporters, a conserved N-linked glycosylation site is not found at the N-terminus of 
MRP7. It has the lowest degree of relatedness to any of the known MRP-related 
transporters. In situ hybridization indicated that MRP7 maps to chromosome 6p12-21, 
in proximity to several genes associated with glutathione conjugation and synthesis. 
On the basis of these findings, MRP7 is included as a member of the MRP subfamily 
of amphipathic anion transporters (Hopper et al., 2001). 
 
Phylogenetic analysis indicates that MRP7 is related to lipophilic anion pumps and 
also involved in the regulation of ion channels (Hopper et al., 2001; Tammur et al., 
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2001). Analysis of MRP7-mediated transport in membrane vesicles prepared from 
transfected HEK293 cells demonstrated that MRP7 was able to catalyze the MgATP-
energized transport of glucuronide E217βG. This facility indicates that it is a 
lipophilic anion pump and a component of the energy-dependent efflux system 
involved in the cellular extrusion of lipophilic compounds that are metabolized by the 
covalent attachment of bulky anionic moieties. Compared with E217βG, only modest 
levels of transport of LTC4 were observed. However, the transport of a range of other 
compounds that are established substrates of other MRP family members can not be 
detected (Chen et al., 2002).  
       1.3.9.    MRP8 
MRP8 (ABCC11) is a recently identified cDNA that has been assigned to the MRP 
family of ATP-binding cassette transporters based on analyses of its predicted protein 
(Bera et al., 2001; Tammur et al., 2001). Like MRP4 and MRP5, MRP8 also lacks a 
third N-terminal membrane spanning domain that is present in other MRP members. 
In addition, sequence comparisons with MRP family members indicate that it most 
closely resembles MRP5 (Bera et al., 2001; Tammur et al., 2001). 
 
Studies demonstrated that MRP8 is an efflux pump for cAMP and cGMP and that it 
not only is able to confer resistance to the purine nucleotide analog PMEA but also 
has the ability to function as a resistance factor for fluoropyrimidines, a widely 
employed class of antineoplastic agents, and the anti-AIDS drug 2’, 3’-
dideoxycytidine (Guo et al., 2003). However, the resistance to 6-thioguanine, an agent 
that is part of the resistance profiles of MRP4 and MRP5, was not detected 
(Wijnholds et al., 2000; Chen et al., 2001). 
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         1.3.10.     MRP9 
In 2002, a newly identified member of the ATP-binding cassette (ABC) superfamily 
was designated as MRP9 (ABCC12) (Bera et al., 2002). The MRP9 sequence, similar 
to that of MRP8, is related closely to MRP5, with an overall 44% identity and 55% 
sequence similarity at the protein level (McAleer et al., 1999). One major difference 
between MRP9 and other MRP members is that MRP9 gene encodes two transcripts 
of different sizes, 4.5 kb and 1.3 kb. In breast cancer, normal breast, and testis, the 
MRP9 gene is 4.5 kb in size and encodes a 100 kDa MRP-like protein that lacks 
transmembrane domains 3, 4, 11, and 12 and the second nucleotide-binding domain. 
In other tissues including brain, skeletal muscle, and ovary, the MRP9 gene size is 
1.3kb. This smaller gene seems to encode the second mucleotide-binding domain of 
about 25 kDa in size. Because MRP9 is a membrane protein and its expression is 
restricted in essential tissues, it could be a useful target for the immunotherapy of 
breast cancer (Bera et al., 2002; Miyake et al., 1999). 
 
 
1.4.     Flavonoids 
Flavonoids have been known as plant pigments for over a century. The first 
observation regarding their biological activities was published in 1936 by Rusznyak 
& Szent-Gyorgyi. Originally proposed to be required as vitamins, the term “vitamin 
P” for flavonoids was suggested, although this was later dismissed. Flavonoids consist 
of a vast group of polyphenolic compounds that are widely distributed in all foods of 
plant origin (Ross and Kasum, 2002).  
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More than 4000 chemically unique flavonoids have been identified in plants. These 
compounds are found in fruits, vegetables, nuts, seeds, and flowers, as well as in 
several beverages, and are important constituents of the human diet. They have 
important effects in plant biochemistry, acting as antioxidants, enzyme regulators, 
precursors of toxic substances, pigments, and light screens, to name a few. Selected 
flavonoids have been shown in numerous in vitro and in vivo experiments to have 
antiallergic, anti-inflammatory, antiviral, and antioxidant activities. In addition, some 
flavonoids have been shown to exert significant anticancer activity, including 
anticarcinogenic and prodifferentiative activities. Flavonoid intake has been shown to 
be inversely related to cardiovascular disease (CVD) risk in epidemiologic studies 
conducted in the Netherlands and Finland. Altogether, a considerable body of 
evidence suggests that plant flavonoids may be health-promoting, disease-preventing 
dietary compounds (Packer et al., 1999).  
The prominent flavonoids in foods are characterized by several subclasses, including 
anthocyanidins, flavanols, flavonones, flavones, flavonols, and their metabolic 
precursors, chalcones. The general structure of flavonoids is two benzene groups 
connected by a three-carbon (propane) bridge.  
There are a limited number of flavonoids within each class that are prominent in plant 
foods commonly consumed by human beings. These include anthocyanidins 
(cyanadin, delphinidin, malvidin), flavan-3-ols (catechin, epicatechin, 
epigalocatechin), flavones (apigenin, luteolin), flavonols (kaemperferol, myricetin, 
quercetin), and chalcones (phloridzin, butein).  
Biological activities of flavonoids have become well known in recent years. Many 
studies suggest that flavonoids have beneficial effects on human health due to their 
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antioxidant capacity and their ability to modulate the activity of different enzymes, 
interact with specific receptors, exert vasodilatory effects, and chelate metal ions such 
as copper and iron. Mega-dose quantities of certain flavonoids are frequently 
consumed by cancer patients as a form of alternative or complementary therapy. They 
are also ingested by healthy individuals as antioxidant supplements. In addition, 
studies have reported that several flavonoids inhibit the transport of LTC4 and 
E217βG by MRP1 but with a different rank order of potency (Leslie et al., 2001).  
Previous studies have shown that various dietary flavonoids stimulate the ATPase 
activity of multidrug resistance protein 1 (MRP1) and inhibit transport of its 
conjugated organic anion substrates but are poor reversers of MRP1-mediated drug 
resistance (Leslie et al., 2001a). In contrast, many of the same flavonoids, such as 
apigenin, naringenin, genistein, and quercetin, markedly stimulate GSH transport by 
MRP1 (Ross and Kasum, 2002). This study also suggests that flavonoids stimulate 
MRP1-mediated GSH transport by increasing the apparent affinity of the transporter 
for GSH but there is no evidence that a cotransport mechanism is involved (Leslie et 
al., 2002). 
Twelve compounds; namely apigenin, catechin, chrysene, curcumin, ellagic acid, 
emodin, epicatechin, genistein, kaempferol, luteolin, narigenin and quercetin were 
used in this study. Table 1.1 shows the structures of these twelve compounds that 









Table 1.1    The structures of the twelve compounds used in the study    
 
















































1.5.    Identification of domains and amino acid residues for 
determining substrate specificity of MRPs 
1.5.1.   Substrate specific domains 
Multidrug resistance protein (MRP) and P-glycoprotein (Pgp) are very distantly 
related members of the superfamily of ATP-binding cassette transmembrane 
transporters. Despite the lack of structural similarity, both proteins confer resistance 
to similar but not identical spectrum of natural product chemotherapeutic agents. The 
substrates of MRPs are structurally unrelated cytotoxic drugs and conjugated organic 
anions. However, what determines the ability of MRPs to transport these substrates 
remains largely unkown. Recently, structure and function studies have begun to 
identify domains and individual amino acid residues involved in determining substrate 
recognition and transport specificity of MRPs. 
 
The two highly conserved NB domains of Pgp play an important role in interaction of 
Pgp with its substrates. Mutations to either of the two NB domains resulted in inactive 
Pgp function (Sun et al., 2004). MRP1-3 consists of 17 transmembrane segments 
(TMs) organized in three membrane-spanning domain regions [MSD1 (TM1-5), 
MSD2 (TM6-11), and MSD3 (TM12-17)] (Deeley and Cole, 1997). The linker region 
between MSD1 and MSD2 was discovered to be necessary for transporting LTC4 by 
using a series of 5’-trucated MRP1 molecules expressed in insect cells (Bakos et al., 
1998; Gao et al., 1998). Unlike the human protein, the murine orthologue of MRP 
(mrp) does not confer resistance to common anthracyclines and is a relatively poor 
transporter of E217βG. However, the hybrid protein obtained by exchanging of 
smaller segments of COOH-terminal third of the mouse protein of amino acid 959-
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1187 or 1188-1531 with those of MRP was capable to confer some level of resistance 
to the tested anthracyclines. These hybrid proteins transported LTC4 and E217βG 
with comparable efficiencies with that of the intact human protein (Stride et al., 1999). 
The cytoplasmic loop (the L0 region in Fig.1.2b) of MRP1 connecting its third NH2-
terminal MSD was required for MRP1 leukotriene C4 (LTC4) transport activity, 
substrate binding and appropriate trafficking of the protein to the basolateral 
membrane by using a baculovirus dual-expression system to produce various 
functionally complementing fragments of MRP1 in insect Sf21 cells and polarized 
MDCK-I cells. Moreover, the study also showed that regions in the cytoplasmic loop 
of MRP1 necessary for LTC4 binding and transport were also required for binding of 
the photoactivable GSH derivative azidophenacyl-GSH (Westlake et al., 2003). 
 
1.5.2.   Identification of key amino acids 
Recently, more detailed analyses of specific amino acid residues involved in MRP 
substrate recognitions, binding and transport were identified. Previous studies 
demonstrated that two hydrogen-bonding amino acid residues, Thr1242 and Trp1246, in 
the predicted transmembrane 17 (TM17) of MRP1 were important for drug resistance 
and E217βG transport. The mutant proteins with Y1236F or T1241A reduced 
resistance to vincristine but not to VP-16, doxorubicin and epirubicin. Mutation 
Y1243F decreased resistance to all tested drugs. Mutation N1245A decreased 
resistance to E217βG, VP-16, doxorubicin and epirubicin but increased resistance to 
vincristine (Zhang et al., 2002).  
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Studies demonstrated that Trp1254 plays an important role in the ability of MRP2 to 
transport conjugated organic anions and identify this amino acid in the putative last 
transmembrane segment (TM17) of this protein as being critical for transport of MTX. 
It was found that nonconservative substitutions (Ala and Cys) of Trp1254 of MRP2 
eliminated E217βG transport, whereas more conservative substitutions (Phe and Tyr) 
had no effect. In addition, only the most conservatively substituted mutant (W1254Y) 
transported leukotriene C4, whereas all other substitutions eliminated transport of this 
substrate, as well as for MTX. Moreover, sulfinpyrazone stimulated E217βG transport 
by wild-type MRP2 up to 4-fold, whereas transport by the Trp1254 substituted 
mutants was enhanced by 6-10-fold (Ito et al., 2001). The importance of the 
hydrogen-bonding potential of residues in TM17 of MRP3 on both substrate 
specificity and overall activity has also been examined. Mutation S1229A reduced 
only methotrexate transport. Mutations S1231A and N1241A decreased resistance to 
VP-16, E217βG and methotrexate but not taurocholate. Mutation Q1235A also 
reduced resistance to VP-16 and E217βG but increased taurocholate transport without 
affecting transport of methotrexate. Mutations Y1232F and S1233A reduced 
resistance to VP-16 and all three substrates tested. In contrast, mutation T1237A 
markedly increased VP-16 resistance and transport of all substrates. Furthermore, 
elimination of the hydrogen-bonding potential of a single amino acid, Thr (1237), 
markedly increased the ability of MRP3 to confer drug resistance and to transport all 
substrates examined (Zhang et al., 2003). Studies done by our group also showed that 
mutations E103N, E103D, R362L and W995C in MRP4 dramatically decreased the 
resistance to MRP4 substrates, 6-TG, dFdC and bimane-GS. Mutation W995F in 
MRP4 only reduced part of the transport activity to bimane-GS (Bai, 2003).  
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To gain further insight into the key amino acids that determine the substrate 
specificity, we aligned the sequence of MRP family (MRP1-8) and focused on the 
charged amino acid residues Arg165, Arg951 and Asp953 (Figure 1.6A-B). In this study, 
we mutated these conserved amino acid residues to conserved or non-conserved 
amino acids to examine the effects on the expression and substrate specificity of 
MRP4. 
  
  1.5.3.   Single-nucleotide polymorphisms (SNPs) in transporters  
A SNP is a site where a single base substitution occurs at a frequency of at least 1% in 
the population. Approximately one out of every 1,900 base pairs in the human genome 
is a SNP, the most common type of variant identified by the Human Genome Project 
(Webb, 2002). Most drug responses are determined by the interplay of several gene 
products that influence pharmacokinetics and pharmacodynamics, such as drug 
transporters. It has been estimated that approximately 500-1200 genes code for 
transporters by sequencing the human genome. In relation to the effects of genetic 
polymorphisms on pharmacotherapy, the best characterized drug transporter is the 
multidrug resistance transporter P-glycoprotein, the gene product of MDR1 (Sakaeda 
et al., 2004). Transporter protein Pgp plays a key role in absorption, tissue targeting 
and elimination of drugs. In addition to physiological and environment contributions, 
its expression and function are modified by genetic polymorphisms of the MDR1 
gene (Eichelbaum et al., 2004). At present, a total of 28 SNPs have been found at 27 
positions on the MDR1 gene, one of which is C3435T. C3435T is also a risk factor 
for a certain class of diseases including the inflammatory bowel diseases, Parkinson’s 
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disease and renal epithelial tumor. This might be explained by the effects on MDR1 
expression and function (Sakaeda et al., 2004). 
The impact of polymorphisms in MRP1 on drug disposition has not been studied 
extensively. A recent study has shown that R433S, a polymorphism in MRP1, 
resulted in a 2-fold reduction in the ATP-dependent transport of LTC4 and estrone 
sulfate and, conversely, a 2-fold increase in resistance to doxorubicin. A number of 
genetic polymorphisms in MRP2 are associated with the Dubin-Johnson syndrome 
(DJS), a condition resulting in hyper-bilirubinemia. However, the relationship of 
mutations in MRP2 to the disposition of chemotherapeutic agents in humans is still 
unknown. Several SNPs in MRP3 was revealed by the combination of GenBank 
cDNA sequence comparison and data from the public SNP database. These SNPs 
have not been functionally characterized, and therefore the clinical impact of such 
MRP3 variants is unknown. Polymorphisms in MRP4 are known to exist including 
C171G, K302N and E757K. However, the impact on drug disposition or 
pharmacodynamics of these polymorphisms remains to be determined. The functional 
characterization of the SNPs in MRP5 and MRP6 is still unknown and the existence 
of SNPs in MRP7, MRP8 and MRP9 is not found so far (Lockhart et al., 2003; Saito 
et al., 2002). 
 
We aligned the sequence of MRP family (MRP1-8) and focused on the SNP encoding 
amino acid residue Cys171 in MRP4 (Figure 1.6C). In this study, we mutated this 
amino acid to Gly to examine the effects on the expression and substrate specificity of 






     
MRP4 160 Q C A G M R L R V A M 
MRP1 389 F V S G M R I K T A V 
MRP2 386 F K L G V K V R T A I 
MRP3 375 F V T G V K F R T G I 
MRP5 244 Y R T G V R L R G A I 
MRP6 375 K V L Q M R L R S A I 
MRP7 146 H H I G M Q M R I A M 
MRP8 381 I E T G I N L R G A I 
 
(B)              
MRP4 946 R W F A V R L D A I 
MRP1 1197 R W L A V R L E C V 
MRP2 1205 R W L A I R L E L V 
MRP3 1193 R W L S I G V E F V 
MRP5 1096 R W L A V R L D L I 
MRP6 1169 R W L A A N V E L L 
MRP7 1097 R W F Q M R I E M I 
MRP8 1245 R W L E V R M E Y I 
 
(C) 
MRP4 166 L R V A M C H M I Y R 
MRP1 395 I K T A V I G A V Y R 
MRP2 391 V R T A I M A S V Y K 
MRP3 381 F R T G I M G V I Y R 
MRP5 250 L R G A I L T M A F K 
MRP6 391 L R S A I T G L V Y R 
MRP7 152 M R I A M F S L I Y K 
MRP8 387 L R G A I Q T K I Y N 
 
 
Figure 1.6    Alignment of predicted TM segments in MRP4 and corresponding TM 
segments in other human MRP family members. The relative conservations of (A) 
Arg165, (B) Arg951 and Asp953 and SNP encoding amino acid of (C) Cys171 in MRP 
family are shown. The arrows indicate the amino acids in the sequences of putative 





2. Aims and overview of study 
 
Multidrug resistance proteins (MRPs) are ATP-dependent export pumps that mediate 
the export of organic anions. A key feature of MRP (ABCC) proteins is the ability to 
transport anionic conjugates including glutathione-S-conjugates. MRP1, MRP2 and 
MRP3 are all able to facilitate the efflux of glutathione-S-conjugates. In a recent study, 
the ability of MRP4 to perform this transport has been extensively investigated (Bai et 
al., 2004). Present studies have demonstrated that MRP4 mRNA show relatively 
ubiquitous expression in human tissues, including the intestinal tract, such as 
duodenum, jejunum and ileum (Prime-Chapman et al., 2004; Zimmermann et al., 
2004), which serves as the site for absorption of nutrients, water, and both beneficial 
and potentially harmful xenobiotics (Kaminsky and Zhang, 2003). This project was 
thus carried out to gain insight into the effects of some common dietary flavonoids on 
the MRP4-mediated efflux of glutathione-S-conjugates and reduced glutathione. In 
addition, the role of highly conserved amino acids and SNP encoding amino acid in 
determination of MRP4 substrate specificity was also examined.  
 
Figure 2.1 shows a flow chart of the approaches used in our project.  Human Hep G2 
cells stably overexpressing MRP4 were used to perform cytotoxic assay as well as 
transport study. The study of transport activity affected by flavonoids was also carried 
out. Furthermore, by using site-directed mutagenesis, we replaced three highly 
conserved amino acids and one SNP encoding amino acid in the MRPs with 
conserved or non-conserved residues. All mutants were stably expressed in 
transfected human Hep G2 cells at levels comparable with wild-type MRP4. The 
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3.    Materials and Methods 
   3.1.   Mammalian cell culture 
        3.1.1.    Materials 
Dulbecco’s Modified Eagle Medium (DMEM), glutamine and penicillin/streptomycin, 
and blasticidin were purchased from National University Medical Institute (NUMI), 
Sigma Chemical Co, USA and Invitrogen, USA respectively. Other cell culture 
reagents were purchased from Life Technologies, USA. 
        3.1.2.    Cell line and cell culture 
The MRP4/Hep G2 clones, which are Hep G2 cells stably expressing human MRP4 
protein, have been previously described (Lai and Tan, 2002). The v/Hep G2 clones, 
which were transfected with pcDNA6 vector and selected by blasticidine, were used 
as the controls in the experiments. Cells were grown in complete medium consisting 
of Dulbecco’s Modified Eagle Medium (DMEM), 1 mM sodium pyruvate, 2 mM 
glutamine, 0.1 mM non-essential amino acids, 100 units/ml penicillin, 100 mg/ml 
streptomycin, 10% fetal bovine serum and 0.25 µg/ml blasticidin and in 37 。 C 
incubator with 95% air and 5% CO2. 
        3.1.3.     Initiating a new flask 
1 ml frozen cells from liquid nitrogen tank were quickly thawed at 37 。 C and 
centrifuged at 1000 x g for 5min with 9ml medium. After the supernatant was 
removed, the pellet was resuspended in a 75cm2 flask with 15ml growing medium and 
kept growing in the 37。C incubator. 
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          3.1.4.     Passaging cells 
When the flask was 80%-95% confluent, the cells were washed twice with 1 x PBS 
(phosphate-buffered saline, 137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4, 1.47mM 
KH2PO4, PH 7.4). After 5min incubation at room temperature with 1.5ml of 1 x 
trypsin, the cells detached from the flask. The cell suspension was then transferred to 
a new 75cm2 flask with 15ml fresh medium.  
           3.1.5.     Harvesting cells 
When cells were 80%-95% confluent in a 75cm2 flask, the cells were washed twice 
with 1 x PBS and trypsinised with 1.5ml 1x trypsin. The detached cells were 
centrifuged at 1000 x g for 5min with 10ml of medium. The cell pellet was kept at –
80。C for further analysis. 
           3.1.6.      Freezing cells  
When cells were 80%-95% confluent, they detached from the 75cm2 flask and were 
centrifuged in the same manner as described above. The cell pellet was resuspended 
in 3ml fetal bovine serum containing 10% DMSO and then transferred to NUNC 
cryotubes and kept at –80。C for one week and then transferred to the liquid nitrogen 
tank for long-term storage.  
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3.2.    Functional study of MRP4 protein 
     3.2.1.      Materials 
6-Thioguanine (6-TG), 6-mercaptopurine (6-MP) and equine liver glutathione-S-
transferase (GST) were purchased from Sigma Chemical Co, USA. Glutathione (GSH) 
was obtained from ICN Biomedicals Inc and monochlorobimane (MCB) was from 
Molecular Probes Inc, USA. [3, (4, 5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium]/ phenazine ethosulfate 
(MTS/PES) reagent was supplied by Promega, USA. Twelve compounds, including 
apigenin, catechin, curcumin, ellagic acid, epicatechin, genistein, kaempferol, luteolin, 
naringenin, quercetin, chrysene and emodin were obtained from Sigma Chemical Co, 
USA.      
 
     3.2.2.     Cytotoxic assay 
5 x 10 3 cells were seeded in each well of a 96-well tissue culture plate with 200µl of 
medium in triplicate. After cells were grown in a 37。C incubator for 24 hours, the old 
medium was substituted with the fresh one with drugs at various concentrations (at 
least five drug concentrations). After incubation for 48 to 72 hours, 20µl of MTS/PES 
was added to each well. The absorbance was measured 30min later at the wavelength 
of 490nm. Each concentration was carried out as two independent experiments 
performed in triplicates. The 50% growth inhibitory concentration (IC50) of the tested 




       3.2.3.      Export assay with MCB 
              3.2.3.1.    Detection and measurement of transport activity 
Measurement of the efflux of bimane-glutathione (bimane-GS) was carried out as 
previously described (Bai et al., 2004). 4 x 10 5 cells were plated in each well of six-
well plates in triplicate and grown for 24h at 37。C. The cells were then incubated 
with 1 ml DMEM containing 100 µM MCB at 10。C for 60min. The plate was put on 
ice and the cells were washed twice with cold Hanks Balanced Salt Solution (HBSS, 
containing 5.8 mM potassium, 143 mM sodium, 1.3 mM calcium, 0.8 mM 
magnesium, 146 mM chloride, 0.8 mM phosphate, 4.2 mM hydrocarbonate，and 10 
mM Hepes, PH 7.4). Then, the cells were incubated at 37。C in HBSS containing 5.6 
mM glucose. At the end of the experiment, the 0.2ml incubation buffer was collected 
and the cells were lysed with 0.2% SDS. The same volume of cell lysate was also 
collected. The fluorescence of all collected samples was read at an excitation 
wavelength of 385 nm and an emission wavelength of 478 nm in a Gemini XS 
microplate spectrofluorometer from Molecular Devices Corp., USA. Protein 
determination was carried out using Bio-Rad protein Dye with bovine serum albumin 
dissolved in 0.2% SDS as the standard. 
 
The amount of bimane-GS was quantified using a series of bimane-GS standards. 0-
48 µM of GSH, 100 µM of MCB, 1U/ml equine liver GST in HBSS buffer (or in 
HBSS buffer containing 0.2% SDS for cell lysate) were mixed in 96-well plate and 
incubated at 37 。 C for 30min till the observed fluorescence did not increase. 
Following this, a calibration curve was obtained and the fluorescence of the samples 
was then correlated with the curve.  
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Cell viability was determined by trypan blue staining at the end of the incubation 
period for efflux. 
             3.2.3.2.        Effects of plant polyphenols on bimane-GS efflux 
To determine the effects of plant polyphenols on bimane-GS efflux mediated by 
MRP4 overexpressing cells, the efflux was carried out as described above in 
HBSS/5.6mM glucose containing 0-100µM plant polyphenols at 37。C for 10min.  
 
        3.2.4.         Reduced glutathione efflux assay 
              3.2.4.1.        Detection and measurement of transport activity  
4 x 10 5 cells were plated in each well of six-well plates in triplicate and grown for 
24h at 37。C. The medium was removed and replaced with 0.6ml HBSS/5.6mM 
glucose/0.5mM acivicin per well. The cells were then incubated at 37。C for 10min. 
The plate was then put on ice and 80µl incubation buffer was collected. After the cells 
were washed twice with cold Hanks balanced salt solution and lysed with 0.6ml 0.2% 
SDS, 80µl lysate was also collected.  
 
To measure the concentration of GSH, the reactions were performed in 96-well plate. 
Each well contained 80µl collected sample, 40µl MCB (1mM)/GST (10U/ml) (1:1 
ratio) mix and 80µl HBSS. The plate was then incubated at 37。 C for 30min. At the 
end of the experiment, the fluorescence was read at an excitation wavelength of 385 
nm and an emission wavelength of 478 nm in a Gemini XS microplate 
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spectrofluorometer. Protein determination was also carried out using Bio-Rad protein 
Dye with bovine serum albumin dissolved in 0.2% SDS as the standard. 
 
The amount of bimane-GS was quantified using a series of bimane-GS standards as 
described in the section 3.2.3.1. 
             3.2.4.2.        Effects of plant polyphenols on GSH efflux 
To determine the effect of plant polyphenols on GSH transport, efflux was carried out 
as described above in HBSS/5.6mM glucose/0.5 mM acivicin containing 0-100µM 
plant polyphenols at 37。C for 10min.  
 
3.3.    Cloning site-directed mutated MRP4 cDNA  
       3.3.1.     Materials 
PCR primers were synthesized by Operon Technologies. INC or GENSET Singapore 
Biotech. Pte Ltd. Luria Broth (LB) medium and 10 x TAE buffer were purchased 
from National University Medical Institute (NUMI). Ampicillin was obtained from 
Sigma (USA). All other reagents were purchased from New England Biolabs, USA. 
The pBluescript vector was obtained from Strategene, USA and pcDNA6 vector and 
blasticidin were purchased from Invitrogen, USA. 
 
     3.3.2.     Site-directed mutagenesis 
              3.3.2.1.    Primer design 
Polymerase chain reaction (PCR) is a technique which is used to amplify the number 
of copies of a specific region of DNA, in order to provide enough DNA to be 
adequately tested. To generate site-directed mutagenesis of the MRP4 open reading 
frame (ORF), PCR was used. Two pairs of primers were designed as follows. One 
pair of primers, the reverse primer (RM) and forward primer (F), was used to amplify 
the DNA that contains the mutation site together with the downstream sequence. The 
second pair of primers, the forward primer (FM) and reverse primer (R), was used to 
amplify the DNA that contains the mutation site together with the upstream sequence. 
Both RM and FM contain the mutation site. Both F and R complement completely to 
the template with a restriction site in the 5’ region and 3’ region, respectively to 
facilitate subcloning of the mutated DNA segment. Primers used for mutagenesis are 
listed in Table 3.1. 
              3.3.2.2.     Polymerase chain reaction (PCR) 
The PCR process, as shown in Figure 3.1, includes two rounds. In the first round PCR, 
which contained two separate reactions, the overlapping fragments containing the 
mutation site were obtained by using two sets of primers. The second round PCR was 
carried out with a mixture of two products from the first round PCR as the template 
by using the two primers F and R to generate a full-length mutant fragment. 
 
PCR was performed using the QIAGEN PCR system. The 50µl mixture consisting of 
5µl 10 x PCR buffer, 1µl 10mM dNTPs mixture, 4µl MgSO4 (25mM), 1µl template 
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DNA (1µg), 1µl of forward and reverse primers (0.2µg/ml), 0.5µl Taq polymerase (5 
units) and 36.5µl ddH2O was prepared in a 200µl PCR tube. The reaction was 
performed in a thermal cycler with the following parameters for 30 cycles: 
 
 
Initial denaturation            94。C                3min 
Denaturation                     94。C                 1min 
Annealing                         55。C                 1min 30 cycles 
Extension                          72。C                 1min/kb DNA 






Figure 3.1   PCR-based overlapping extension to produce mutants 
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Table 3.1   Primers for mutagenesis. Substituted nucleotide are underlined; small 
letters indicate restriction enzyme recognition sequence. 
 
 
Name of mutant Primers 
R165K 
(Original amino acid R was 
mutated to amino acid K) 
F: 5’ TGC gaa ttc ATG CTG CCC GTG TAC CA 3’ 
 
RM: 5’ TAC TCG TAA CTT CAT CCC AGC 3’ 
 
FM: 5’ GCT GGG ATG AAG TTA CGA GTA 3’ 
  
R: 5’ TGT gat atc TCA TCA AGT A 3’ 
 
R165N 
(Original amino acid R was 
mutated to amino acid N) 
F: 5’ TGC gaa ttc ATG CTG CCC GTG TAC CA 3’ 
 
RM: 5’ TAC TCG TAA GTT CAT CCC AGC 3’ 
 
FM: 5’ GCT GGG ATG AAC TTA CGA GTA 3’  
 
R: 5’ TGT gat atc TCA TCA AGT A 3’ 
 
C171G 
(Original amino acid C was 
mutated to amino acid G) 
 
F: 5’ TGC gaa ttc ATG CTG CCC GTG TAC CA 3’ 
 
RM: 5’ AT CAT ATG ACC CAT GGC TA 3’ 
 
FM: 5’ TA GCC ATG GGT CAT ATG AT 3’ 
 
R: 5’ TGT gat atc TCA TCA AGT A 3’ 
 
R951M 
(Original amino acid R was 
mutated to amino acid M) 
 
F: 5’ CTT gtt aac TCT TCA CAA 3’ 
 
RM: 5’ GC ATC CAG CAT GAC GGC GAA 3’ 
 
FM: 5’ TTC GCC GTC ATG CTG GAT GC 3’ 
 
R: 5’ TGT ctc gag GAT TCC CAG TGC TGT CTC 3’ 
 
D953Q 
(Original amino acid D was 
mutated to amino acid Q) 
 
 
F: 5’ CTT gtt aac TCT TCA CAA 3’ 
 
RM: 5’ C ACA GAT GGC TTG CAG ACG 3’ 
 
FM: 5’ CGT CTG  CAA  GCC ATC TGT G 3’ 
 






                3.3.2.3.         Extraction and purification of DNA 
To ensure the correct size of the products, gel electrophoresis was used. Agarose 
(BioRad) was dissolved in 1 x TAE buffer (Tris-Acetate-EDTA: 4mM Tris, 0.2mM 
EDTA and 1.14‰ glacial acetic acid with pH at 7.8) with 500µg/L ethidium bromide 
(BioRad) for staining to get 1% agarose gel. Electrophoresis was performed at 100 
volts for 50min and a photograph of the gel was taken on the UV transilluminator. 
 
DNA gel extraction and purification was performed with QIAquick Gel Extraction 
Kit (QIAGEN). After electrophoresis, the DNA fragment of interest was excised and 
weighed. The gel slice was dissolved in 3 volumes of buffer QG and loaded onto a 
QIAquick column in a 2-ml collection tube to bind the DNA. After the tube was 
centrifuged at 14,000rpm for 1 minute, 0.75ml of buffer PE was added to the column 
and the tube was centrifuged twice to allow the buffer PE to flow through completely. 
The column was then placed in a clean 1.5ml tube. 30µl of buffer EB were added 
directly into the column to elute the DNA. After standing for several minutes at room 
temperature, the column was centrifuged again at 14, 000rpm for 1 minute to collect 
the eluted DNA. 
 
3.3.3.       TA sub-cloning 
               3.3.3.1.     Ligation of PCR products to a TA cloning vector 
The pGEM-T vector (Promega) with unpaired thymidyl residue at the 3’ end was used 
for TA cloning for its character to be readily ligated with PCR products containing the 
additional single adenine at the 5’ end generated by Taq polymerase. An ampicillin 
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resistance gene and a β-galactosidase gene were contained in the vector for 
ampicilline and blue/white selection. 
 
 
Figure 3.2   The map of the pGEM-T vector (Promega).  
 
1µl pGEM-T vector (60 ng), 1µl T4DNA ligase (5 units), 5µl 2x rapid ligase buffer 
and 3µl PCR product purified by gel extraction were mixed together and incubated at 
room temperature for at least 2 hours. 
3.3.3.2.       Culture of bacterial cells 
Luria Broth (LB) containing 10g of tryptone, 5g of NaCl, and 5g of yeast extract in 
1L sterile water with pH at 7.4 was used for bacterial culture. LBA (LB with 
ampicillin) medium and LBA-agar plate containing 100µg/ml ampicillin were used 
for the selection of cells carrying the vector. All preparations were kept at 4。C before 
use. DH5α, a strain of E.coli, is the bacteria used for transformation. The bacteria was 
incubated in LB/LBA medium, or streaked on LB/LBA agar plates. Frozen stocks in 
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LB/LBA medium containing 10% sterile glycerol were kept at –20。C for long-term 
storage. 
                 3.3.3.3.      Preparation of competent cells 
A single colony was picked from a freshly streaked plate and inoculated into 3ml of 
LB medium which was incubated at 37。C overnight with vigorous shaking at 200 x g. 
The next day, 1ml of the bacteria culture was transferred into another 20ml of LB and 
incubated at 37。C with vigorous shaking for 40min until the absorbance value of the 
culture reached 0.3-0.4 at 600nm. After centrifugation at 3,000 x g for 5min at 4。C, 
the cells were harvested and resuspended in 5ml of ice-cold 0.1M CaCl2. After 15min 
incubation on ice, the cells were centrifuged again and the pellet was resuspended in 
1ml of ice-cold 0.1M CaCl2. After another 15 minutes incubation on ice, the 
competent cells were ready for transformation.  
                 3.3.3.4.       Transformation 
25µl sterile TE buffer were added to 5µl of the ligation product to decrease the 
concentration of glycerol in the ligase buffer. 200µl of competent cells were added to 
30µl of the diluted sample and allowed to stand on ice for 30min. Then, the sample 
was incubated in a 37。C water bath for 3 minutes and promptly transferred back on 
ice. After 5 minutes, 250µl of LB were added and the sample was incubated at 37。C 
with vigorous shaking for 45min. After the mixture containing 1.25mg X-gal (Bio-
Rad) and 5nmol IPTG (Sigma) was spread onto a LBA plate, 300µl of transformed 
cells were spread on the plate which was incubated at 37。C overnight. 
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                3.3.3.5.         Selection and screening 
The next day, single white colonies were picked and inoculated into 3ml LBA 
medium in 15ml tubes with the loose caps. The cultures were incubated overnight at 
37。C with vigorous shaking and used for further analysis.  
              3.3.3.6.        DNA extraction:  mini-prep 
1ml bacteria culture was centrifuged at 12,000 x g for 1 minute and the bacteria pellet 
was resuspended in 100µl of ice-cold solution Ι (25mM Tris, 10mM EDTA and 
50mM glucose, pH 8.0) by vigorous vortexing. 200µl of solution ІІ (0.2M NaOH and 
0.1%SDS) were then added and the tube was immediately inverted 5-6 times to mix 
the contents completely. After incubated on ice for 5 minutes, 150µl of ice-cold 
freshly prepared solution Ш (3.0M potassium acetate and 0.5M acetic acid, pH 4.8) 
were added and the tube was then inverted 5-6 times to mix. Following 5 minutes 
incubation on ice, the tube was centrifuged at 14,000 x g for 5 minutes and the 
supernatant was transferred to a new tube. 0.9ml of 100% ethanol was then added and 
the mixture was vortex shortly to precipitate the DNA. After 5 minutes incubation at 
room temperature, the tube was centrifuged at 14,000 x g for another 5 minutes and 
the pellet was rinsed with 1ml 70% ethanol. The tube was then centrifuged again. 
After the supernatant was removed carefully, the pellet was dried in the speed-Vac for 
10-15 minutes and then dissolved in 25µl TE buffer containing 20µg/ml RNase 
(Promega). The DNA sample was stored at –20。C for further analysis.  
               3.3.3.7.        Restriction enzyme digestion  
The plasmid was digested with the appropriate restriction enzymes (NEB), including 
EcoRΙ and EcoRV for clones R165K, R165N and C171G, HincІІ and XhoΙ for clones 
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R951M and D953Q. The appropriate digestion buffer was used for each digestion. 
0.25µl (2-5 units) of each enzyme, 1µl of 10 x buffer, 3µl (1-2 µg) of DNA template 
and 4.5µl of sterile water were mixed and incubated at 37。C for 2-3 hours. The 
correct size of the digested fragments was confirmed by agarose gel electrophoresis.  
3.3.3.8.          DNA extraction: midi-prep 
Midi-prep was employed for a larger scale plasmid preparation and purification with 
QIAGEN midi plasmid preparation kit. 1ml bacteria culture was grown in 100ml of 
LBA medium at 37。C with vigorous shaking overnight. The next day, bacteria cells 
were harvested by centrifugation at 5,000rpm for 15 minutes at 4。C. The cell pellet 
was resuspended in 4ml ice-cold buffer P1 by pipetting up and down. 4ml of buffer 
P2 were added and the tube was then inverted 4-6 times to mix the contents and 
incubated at room temperature for 5 minutes. 4ml of ice-cold buffer P3 were added 
and the tube was inverted 4-6 times again and incubated on ice for 15-20 minutes. 
Then, the tube was centrifuged at 13,000rpm for 30 minutes at 4。C. A QIAGEN-tip 
100 column was equilibrated with 4ml of buffer QBT in advance before the 
supernatant was transferred to and was allowed to flow through the column by gravity. 
The column was then washed twice with 10ml buffer QC each time and the DNA was 
eluted with 5ml buffer QF. The eluant was collected in a new tube and mixed with 
3.5ml isopropanol (Sigma), then centrifuged again immediately at 13,000rpm for 30 
minutes. The pellet was rinsed with 1ml 70% ethanol and transferred to a 1.5ml tube. 
After the tube was centrifuged at 14,000 x g for 10 minutes, the pellet was dried in the 
speed-Vac and dissolved in 100µl TE buffer.  
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The concentration and the purity of plasmid DNA obtained from midi-prep were 
determined by measuring the absorbance at 260 nm and 280 nm. The DNA was 
digested with the appropriate restriction enzyme and the correct size and sequence of 
digested fragments were confirmed by agarose gel electrophoresis analysis and DNA 
sequencing. The remainder DNA was stored at –20。C. 
 3.3.3.9.         DNA sequencing 
BigDye TerminatorTM Cycle Sequencing Ready Reaction Kit obtained from ABI 
PRISM Corp (USA) was used for DNA sequencing. 4µl of Big Dye, 2µl 5 x 
sequencing buffer, 1µl of DNA template, 1µl of 50µM forward or reverse primer and 
10µl of ddH2O were mixed and subjected to PCR amplications using the following 
program: 25 cycles of denaturation at 96。C for 30sec, annealing at 50。C for 15sec 
and extension at 60。C for 4min. To precipitate the extended DNA, 3µl of 3 M sodium 
acetate and 50µl of 95% ethanol were used. After 15 minutes of incubation at room 
temperature, the sample was centrifuged at 14,000 x g for 30min. The supernatant was 
carefully aspirated and the pellet was rinsed with 250µl 70% ethanol and centrifuged 
for 5min again. The air-dried sample was sent to the NUMI sequencing lab for 
sequencing. The result was compared to the published MRP4 sequence (GenBank 
access number AF071202). 
        3.3.4.         Plasmid construction 
pBlueScript SK ІІ (+) (pBS) with the cloning sites of EcoRΙ, EcoRV, HincІІ and XhoΙ 
present sequentially is a cloning vector used to subclone MRP4. pcDNA6/V5-His 
(pcDNA6) is an eukaryotic expression vector with the V5 epitope and a polyhistidine 
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sequence at the end of multiple cloning site that can be used to obtain the fusion 
MRP4-V5 protein. (Figure 3.3) 
 
Figure 3.3   The map of pcDNA6/V5-His vector (Invitrogen). The EcoRΙ and XhoΙ 
sites are used for cloning the MRP4 full-length gene. 
 
Full-length MRP4 cDNA had been subcloned into pBS and pcDNA6 vector to 
generate MRP4-pBS and MRP4-pcDNA6 constructs. EcoRΙ and XhoΙ restriction sites 
were at the 5’- and 3’- ends of MRP4 cDNA, respectively. The mutated fragments 
with the restriction enzyme sites of EcoRΙ and EcoRV at each end were digested from 
the insert in pGEM-T vector and inserted directly into MRP4-pcDNA6. However, the 
mutated fragments with the restriction enzyme sites of HincІІ and XhoΙ at each end 
had to be transferred to MRP4-pBS construct firstly before being ligated into the 
expression vector since the HincІІ restriction enzyme site is a unique site in pBS and 
MRP4 but is a multiple site in pcDNA6. The MRP4-pBS construct containing the 
mutant was then digested by EcoRV and XhoΙ and the digested fragment was then 
inserted into the digested pcDNA6 with the same enzymes. The full-length MRP4-
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pcDNA6 constructs with the mutation sites were sequenced again and used for 
mammalian cell transfection.  
 
 
               RRR 
 
Figure 3.4   Schematic diagram of full-length MRP4 with restriction enzyme sites. 
EcoRI restriction enzyme site was before the start codon of MRP4 cDNA sequence 
and XhoI restriction enzyme site was after the last codon of the MRP4 cDNA.  
EcoRV and HincII are the unique restriction enzyme sites within the MRP4 cDNA. 
 
      Indicates the amino acid site where site-directed mutagenesis was performed.  
  
3.4.    Transfection and expression of mutated MRP4 
          3.4.1.    Materials 
OPTI-MEM Ι Reduced Serum Medium, Lipofectamine reagent, anti-V5 monoclonal 
antibody and anti-V5-FITC monoclonal antibody were purchased from Invitrogen, 
USA.  
          3.4.2.    Transfection and selection 
Mutant MRP4-pcDNA6 was transfected into Hep G2 cells. Wild type MRP4 and 
empty pcDNA6 vector was also transfected as the controls. One day before 
transfection, 3 x 10 5 Hep G2 cells were plated into six-well plates (35-mm) per well. 
4µg of DNA of each sample precipitated from midi plasmid preparation was 
dissolved in 100µl of OPTI-MEM Ι Reduced Serum Medium while 6µl of 
Lipofectamine reagent was diluted with another 100µl of OPTI-MEM medium for 
 
(EcoRΙ)                   EcoRV                                    HincII                                 XhoI
 
R165K  C171G                                                   R951M D953Q 
R165N                     
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each transfection. These two were then mixed gently and incubated at room 
temperature for 45 minutes to allow DNA-liposome complexes to form. Before 200µl 
of the mixture were gently added into each well, cells in the six-well plates were 
washed twice with the OPTI-MEM medium and incubated in 0.8ml of OPTI-MEM 
medium. After 5 hours of incubation at 37。C, 2ml of complete DMEM medium were 
added into each well without removing the transfection mixture and the cells were 
incubated overnight. On the second day, the old medium was changed with fresh 
complete DMEM medium. From the third day, complete DMEM medium with 
1µg/ml blasticidin for selection was changed every 2 days for about 3 weeks to allow 
the resistant cells to grow. When single colonies were obviously observed, they were 
picked up and transferred individually into a 96-well plate to allow them to expand 
until there were sufficient cells to grow in a 75cm2 flask. Localization and expression 
levels of MRP4 protein in the blasticidin-resistant cells were then determined by 
immunostaining and western blotting analysis. 
       3.4.3.       SDS-PAGE gel electrophoresis 
              3.4.3.1.      Preparation of reagent and solution  
To prepare 4x buffer for separating gel (1.5 M Tris-HCl), 18.17g Tris base were 
dissolved in 100ml H2O and adjusted to pH 8.8 with 6N HCl. To prepare 4x buffer for 
stacking gel (0.5 M Tris-HCl), 6g Tris base was dissolved in 100ml H2O and adjusted 
to pH 6.8 with 6N HCL. To prepare 10 x  polyacrylamide running buffer, 30g Tris 
base, 144g glycine and 100ml 10% SDS were dissolved in 1L H2O. To prepare 4x 
sample buffer, 0.0185g bromophenol blue, 0.8g SDS, 10ml 4x stacking buffer, and 
8ml glycerol were mixed together and completely dissolved. Acrylamide solution 
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(30%) consists of 30g acrylamide and 0.8g bisacrylamide in 100ml H2O. 10% AP 
(ammonium persulfate from Sigma) solution was prepared freshly just before use.  
                3.4.3.2.      Preparation of sample 
When cells showed about 70%-80% confluence in a 75cm2 flask, 0.5-1ml 1x PBS 
with 2% Triton X-100 was added into the flask to ensure the bottom of the flask were 
covered. The flask was allowed to stay on ice for about 10 minutes till all the cells 
were lysed. The cell mixture was taken out from the flask and centrifuged at 
14,000rpm at 4。C for 20min. After that, the supernatant was collected as the samples. 
To ensure that the same amount of protein from different samples was applied, protein 
determination was carried out using the Bio-Rad Protein Dye with bovine serum 
albumin as the standard. About 30µl of supernatant (corresponding to about 0.1mg 
protein) was mixed with 10µl of SDS 4x sample buffer and 1.5µl β-mercaptoethanol. 
                3.4.3.3.       Procedure 
A 10% resolving gel solution was mixed and allowed to degas before AP and 
TEMED were added. The reagents were quickly mixed and poured into a mini-gel 
casting chamber till the depth of 2.5 cm from the top. Water was overlaid to cover the 
separating gel. When the separating gel had solidified, the prepared stacking gel was 
poured on top of the separating gel after the water was removed. A comb was inserted 
into the stacking gel. After the stacking gel solidified, the comb was removed. The gel 
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20µl of sample or 10µl of prestain protein ladder (BioRad) was loaded into each well. 
The gel was then electrophoresised at 140 volt for 60 minutes or till the dye front ran 
near the bottom of the gel.  
 
     3.4.4.     Western blotting 
The separation gel was soaked in the transfer buffer (25mM Tris, 0.2 M glycine, 
0.05% SDS and 20% methanol, pH 8.3) together with the nitrocellulose membrane 
and filter paper of the same size as the gel for about 40min. The gel sandwich was 
stacked in the order of filter paper, gel, membrane and filter paper. The proteins were 
transferred from gel onto nitrocellulose membrane at 350 mA for 60 minutes at 4。C. 
The membrane was then blocked overnight in blocking buffer (TBS-T buffer with 5% 
skim milk). After washing with TBS-T buffer (20mM Tris, 137mM NaCl and 0.1% 
Tween-20, pH 7.4) twice, the membrane was cut to two pieces to separate the MRP4 
protein (about 150 KD) from actin (52 KD). 
 
The membrane was then incubated in 5ml of blocking buffer containing 1:1000 
diluted anti-V5 antibody (Sigma, USA) for MRP4 or 1:500 diluted anti-actin antibody 
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(Sigma, USA) for 2 hours. The membrane was then washed with TBS-T buffer three 
times and then incubated in blocking buffer containing 1:2000 diluted goat anti-
mouse antibody (BioRad) for MRP4 or 1:5000 diluted anti-rabbit antibody for actin 
(ECL kit, Amersham) for 1 hour. The membrane was then thoroughly washed with 
TBS-T buffer to remove the excess secondary antibody. Finally the membrane was 
submerged in the mixture containing equal volumes of luminol solution and stable 
peroxide solution (ECL kit, Amersham) and incubated for 5min. The membrane was 
removed from the mixture and placed against the film (Kodak) in the cassette. The 
film was developed after sufficient exposure, usually less than 1min for actin and 
10min for MRP4.  
 
Relatively levels of protein expression were estimated by densitometric analysis using 
the Analytical Imaging Station software (Imaging Research Inc, USA). 
 
      3.4.5.        Immunostaining 
Cells were grown on a chamber slide until 50% confluence. Cells were first fixed with 
methanol for 20 minutes at –20。C. After washing 4 times (5min for each washing), 
the cells were permeablized with 0.02% Triton X-100 (BioRad) in cold PBS buffer 
for 15 minutes. After washing 4 times, the cells were blocked with PBS containing 
10% FBS for 20 minutes to reduce non-specific binding of antibody. After removing 
the blocking solution, the cells were stained with anti-V5 antibody conjugated to 
FITC diluted in the ratio of 1:200 in PBS buffer containing 10% FBS for 1 hour in the 
dark. Cells were then thoroughly washed 4 times. To counter stain, cells were 
incubated in mounting solution with propidium iodide (Vector Laboratories, Inc., 
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USA) for 10 minutes and then viewed with a fluorescence microscope. The FITC-
conjugated antibody has an excitation wavelength of 495 nm and an emission 
wavelength of 525 nm. 
3.5.      Functional study of mutated MRP4 protein 
     3.5.1.     Cytotoxic assay 
Measurement of cell growth inhibition was carried out as previously described in 
section 3.2.2.1. Two drugs: 6-TG and 6-MP were used.  
 
      3.5.2.     Export assays with MCB 
Measurement of the formation and efflux of bimane-glutathione (bimane-GS) was 
carried out as described in section 3.2.3.1.    
 
3.5.3.    Export assays of GSH 









4.        Results 
 
4.1.       Functional study of MRP4 protein 
   4.1.1.      Export of bimane-GS by MRP4/Hep G2 cells 
Monochlorobimane (MCB) has been shown to form a fluorescent adduct with GSH 
specifically and preferentially over thiols by glutathione-S-transfereases (Fernandez-
Checa et al., 1990). After diffusing into the cell and conjugating with GSH, the 
resulting hydrophilic bimane-glutathione can only leave the cell via carrier-mediated 
transport (Zhang et al., 1996; Terlouw et al., 2001; Ishikawa et al., 1994). In this 
study, the formation and efflux of the fluorescent bimane-GS adduct was examined 
using MRP4 overexpressing cells (MRP4/Hep G2). Cells stably transfected with the 
empty pcDNA6 vector (v/Hep G2) served as the controls.  
 
Cells were loaded with 100µM MCB at 10。C to ensure that little active efflux of the 
bimane-GS will take place. After warming to 37。C, a time-dependent efflux of 
bimane-GS was observed. Amount of bimane-GS efflux from MRP4/Hep G2 cells 
increased from 12.8 ± 0.9 nmol/mg protein to 40.3 ± 0.9 nmol/mg protein over a 
period of 20min (Figure 4.1A), while cellular bimane-GS levels decreased from 40.3 
± 0.7 nmol/mg protein to 15.6 ± 0.5 nmol/mg protein (Figure 4.1B). After 20min, 
more than 72% of the conjugate has been transported out of the cell (Figure 4.1C). 
The efflux of bimane-GS from MRP4/Hep G2 cells is rapid and the rate of efflux 
tapered off after 10min. Thus, all subsequent bimane-GS export assays were carried 
out after 10min of incubation at 37。C. In contrast, the efflux from v/Hep G2 increased 
gradually from 8.3 ± 0.2 nmol/mg protein to 25.2 ± 0.7 nmol/mg protein over the 
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same period (Figure 4.1A). Export of bimane-GS from v/Hep G2 cells is probably 
mediated by endogenous MRP proteins which are expressed in Hep G2 cells (Lee et 
al., 2001; Roelofsen et al., 1997). At all time points beyond 0 min, the export of 
bimane-GS from MRP4/Hep G2 cells was significantly higher than that from v/Hep 
G2 cells but the total synthesis of bimane-GS in MRP4/Hep G2 cells (55.9 ± 0.7 





















































































Figure 4.1 Efflux of bimane-glutathione from control and MRP4 overexpressing cells.   
(A) Bimane-GS exported into the incubation buffer and (B) intracellular bimane-GS 
were measured over a 20-min time course. The percent efflux was calculated by 
taking the ratio of the amount of bimane-GS efflux to that of the total bimane-GS 
(sum of bimane-GS in incubation buffer and cell lysate) and multiplying by 100%. 
Percent efflux at each time point is shown in (C). The solid line shows the values 
from MRP4/Hep G2 cells and the broken line shows the values from v/Hep G2 cells. 
All points for MRP4/Hep G2 cells with the exception of that at 0 min were 
significantly different from that observed for v/Hep G2 cells (ANOVA analysis, 




4.1.2.      Effects of plant polyphenols on bimane-GS efflux mediated 
by MRP4 
 
Plant polyphenols have been shown to stimulate the ATPase activity of multidrug 
resistance protein 1 (MRP1), inhibit transport of its conjugated organic anion 
substrates, and stimulate GSH transport by MRP1 (Ross and Kasum, 2002). In this 
study, the effects of twelve compounds at different concentration (0, 10, 50 and 
100µM) were also been examined. The twelve compounds were apigenin, catechin, 
chrysene, curcumin, ellagic acid, emodin, epicatechin, genistein, kaempferol, luteolin, 
naringenin and quercetin. Five of them had a concentration-dependent inhibition of 
bimane-GS efflux mediated by MRP4 (Figure 4.2A and B). The presence of 10, 50 
and 100µM curcumin led to a decrease in bimane-GS efflux by 24.8%, 50.4% and 
65.3% respectively (Table 4.1). The presence of 50 and 100µM ellagic acid led to a 
decrease in bimane-GS efflux by 21.8% and 26.3%, respectively (Table 4.2). The 
presence of 50 and 100µM kaempferol led to a decrease in bimane-GS efflux by 
16.7% and 42.0%, respectively (Table 4.3). The presence of 100µM luteolin led to a 
decrease in bimane-GS efflux by 33.1% (Table 4.4). The presence of 100µM apigenin 
led to a decrease in bimane-GS efflux by 31.5% (Table 4.5). These five compounds 
had no effect on the synthesis of bimane-GS and corresponding increases in cellular 
bimane-GS accumulation were also observed. No obvious effects on bimane-GS 
export were observed with the other seven compounds used in this study. These 
include epicatechin, naringenin, catechin, chrysene, emodin, genistein and quercetin 
(Table 4.6).  Cell viability as determined by trypan blue staining was not affected in 
all of above experiments. 
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0 (control) 50.7±0.8/ 23.1±0.4 35.2±0.4 12.1±0.8 
 50.1±0.3   [0%] 
     
10 49.2±0.8/ 19.4±0.1* 28.5±0.4* 9.1±0.4* 
 51.5±0.8   [24.8%] 
     
50 52.1±1.2/ 17.1±0.5* 23.2±0.5* 6.0±0.4* 
 50.3±1.0   [50.4%] 
     
100 50.3±1.1/ 13.6±0.3* 17.3±0.3* 4.2±0.2* 
 53.7±1.0   [65.3%] 
 
Cells were incubated in 1ml DMEM containing 100µM MCB at 10。C for 1 hour. The 
medium was then removed and efflux was carried out at 37。C in HBSS buffer 
containing 5.6mM glucose and different concentration curcumin for 10min. The 
difference between the efflux from MRP4/Hep G2 and that from v/Hep G2 cells 
represents the efflux mediated by MRP4. Values shown are expressed as means ± SD 
from three independent determinations. (*)Compared with the corresponding 
untreated cells, P<0.05, ANOVA analysis. 
 
 


































0 (control) 48.0±1.0/ 22.9±0.5 38.5±0.3 15.6±0.8 
 51.1±0.6   [0%] 
     
10 48.7±1.0/ 23.2±0.6 37.2±0.7 14.1±0.7 
 49.8±0.9   [9.6%] 
     
50 50.1±0.6/ 19.5±0.4* 31.7±0.8* 12.2±0.4* 
 48.8±1.1   [21.8%] 
     
100 52.3±1.4/ 19.1±0.6* 30.6±0.8* 11.5±0.5* 
 49.2±1.3   [26.3%] 
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0 (control) 48.0±1.0/ 24.5±0.4 38.3±0.6 13.8±0.3 
 48.1±0.8   [0%] 
     
10 44.5±0.8/ 20.4±0.6* 34.1±0.6* 13.7±1.1 
 46.3±0.7   [0.7%] 
     
50 43.2±1.3/ 15.5±0.4* 27.0±0.3* 11.5±0.6* 
 45.2±0.5   [16.7%] 
     
100 47.3±0.7/ 11.1±0.2* 19.2±0.4* 8.0±0.8* 










































0 (control) 53.0±1.1/ 27.2±0.4 42.0±0.6 14.8±0.5 
 52.4±1.4   [0%] 
     
10 52.4±1.5/ 25.1±0.7* 38.5±0.5* 13.4±1.1 
 50.3±0.8   [9.5%] 
     
50 50.2±0.9/ 22.1±0.4* 34.7±0.8* 12.6±0.6 
 51.9±0.7   [14.9%] 
     
100 50.6±1.2/ 21.1±0.3* 31.0±0.9* 9.9±0.8* 








































0 (control) 44.3±0.7/ 20.0±0.5 32.4±0.8 12.4±0.7 
 45.9±1.1   [0%] 
     
10 46.0±1.6/ 20.0±0.6 30.8±1.2* 10.8±1.1 
 45.1±1.3   [12.9%] 
     
50 43.3±0.5/ 16.9±0.2* 27.4±1.1* 10.5±0.6 
 45.9±1.1   [15.3%] 
     
100 43.1±1.3/ 15.2±0.6* 23.6±0.6* 8.5±0.8* 








Table 4.6   Compounds which did not have any effects on bimane-GS efflux (data 




































catechin(0) 54.4±1.0/ 22.8±0.3 34.9±0.6 12.1±0.5 
 54.8±1.1    
catechin(100) 52.4±1.0/ 21.8±0.3 35.6±0.6 13.8±0.8 
 56.2±0.7    
     
chrysene(0) 48.0±1.0/ 22.9±0.5 38.5±0.3 15.6±0.8 
 51.1±0.6    
chrysene(100) 52.7±1.0/ 25.2±0.5 38.7±1.0 13.5±0.8 
 51.6±1.4    
    
emodin(0) 52.1±0.3/ 17.6±0.2 28.5±0.2 11.0±0.1 
 53.2±0.4    
emodin(100) 53.2±0.6/ 17.7±0.3 28.0±0.7 10.2±1.0 
 52.6±1.2    
     
genistein(0) 53.0±0.5/ 19.4±0.5 30.1±0.5 10.7±0.5 
 54.4±0.7    
genistein(100) 53.9±0.5/ 19.3±0.3 30.7±0.4 11.3±0.2 
 55.5±0.6    
     
quercetin(0) 55.4±0.9/ 19.4±0.4 30.7±0.3 11.2±0.6 
 57.4±0.6    
quercetin(100) 53.9±0.9/ 18.7±0.3 29.1±0.3 10.4±0.3 
 55.1±0.7    
     
epicatechin(0) 45.3±0.6/ 21.8±0.5 36.1±0.6 14.3±0.5 
 48.2±1.1    
epicatechin(100) 46.6±0.9/ 22.3±0.9 35.6±0.5 13.3±0.8 
 47.9±0.9    
     
naringenin(0) 44.7±1.1/ 20.5±0.8 32.9±0.8 12.4±0.5 
 46.6±1.1    
naringenin(100) 47.1±1.6/ 22.0±1.0 33.3±0.7 11.3±0.8 



















































Figure 4.2   Effects of polyphenols on bimane-glutathione efflux. Cells were 
preincubated with medium containing 100 µM of MCB at 10。C. The medium was 
then replaced with HBSS containing 5.6 mM glucose and 0-100 µM compounds and 
incubated at 37。C for 10min. (A) Effect of apigenin, kaempferol and luteolin on 
ABCC4-mediated export of bimane-GS. (B) Effect of curcumin and ellagic acid on 
ABCC4-mediated export of bimane-GS. The open bars show the values in the 
absence or in the presence of apigenin, the black bars show the values in the absence 
or in the presence of kaempferol, the horizontal striped bars show the values in the 
absence or in the presence of luteolin, the dotted bars show the values in the absence 
or in the presence of curcumin and the vertical striped bars show the values in the 
absence or in the presence ellagic acid. Values shown are means ± SD of two 
independent experiments performed in triplicates. (*)  Indicates P<0.05 (ANOVA 
analysis) when compared to the corresponding controls in the absence or in the 
presence of compounds.   
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4.1.3.     Export of reduced glutathione by MRP4/Hep G2 cells 
 
Reduced glutathione (GSH) plays an important role in the protection of cells from 
oxidative stress. The transport of some toxin and drugs by MPR proteins requires the 
presence of GSH. Both MRP1 and MRP2 have the ability to transport glutathione 
(Leslie et al., 2003; Kruh and Belinsky, 2003). In this study, the efflux of the reduced 
glutathione was examined using MRP4 overexpressing cells and carried out in the 
presence of 0.5mM acivicin to inhibit the γ-glutamyltranspeptidase, an enzyme 
present on the external surface of apical membranes that hydrolyses excreted GSH 
(Michael et al., 1999). Cells transfected with empty pcDNA6 vector (v/Hep G2) were 
used as the control. The efflux of GSH was investigated by examining the fluorescent 
bimane-GS adduct formed following the reaction with MCB as shown below. 
  
GSH in medium                        bimane-GS (fluorescent adduct) 
      
Amount of GSH efflux from MRP4/Hep G2 cells increased from 10.2 ± 0.2 nmol/mg 
protein to 20.5 ± 0.5 nmol/mg protein over a period of 15min (Figure 4.3A). This is 
mirrored by a decrease in cellular GSH levels from 40.5 ± 1.7 nmol/mg protein to 
32.0 ± 1.7 nmol/mg protein (Figure 4.3B). The efflux of GSH from MRP4/Hep G2 
cells is rapid and the rate diminishes after 10min. Thus, all subsequent GSH export 
assays were carried out after 10min of incubation at 37。C. After 15min, about 39% of 
the glutathione has been transported from the cell (Figure 4.3C). In contrast, the efflux 
from v/Hep G2 increased more gradually from 6.5 ± 0.4 nmol/mg protein to 12.3 ± 
0.6 nmol/mg protein over the same period (Figure 4.3A). The export of GSH from 




in Hep G2 cells. At all time points beyond 0 min, export of GSH from MRP4/Hep G2 
cells was significantly higher than that from v/Hep G2 cells but the total GSH levels 
in MRP4/Hep G2 cells (52.5 ± 1.2 nmol/mg protein/15min) was comparable to that in 













































































Figure 4.3   Efflux of GSH from control and MRP4 overexpressing cells.   
(A) GSH exported into the incubation buffer and (B) intracellular GSH were 
measured over a 15-min time course. The percent efflux was calculated by taking the 
ratio of the amount of GSH in the incubation buffer to that of the total GSH (sum of 
GSH in incubation buffer and cell lysate) and multiplying by 100%. Percent efflux at 
each time point is shown in (C). The solid line shows the values from MRP4/Hep G2 
cells and the broken line shows the values from v/Hep G2 cells. All points for 
MRP4/Hep G2 cells with the exception of that at 0min were significantly different 
from that observed for v/Hep G2 cells (ANOVA analysis, P<0.05). Values shown are 







4.1.4.      Effects of plant polyphenols on GSH efflux mediated by 
MRP4 
Plant polyphenols have been shown to stimulate the ATPase activity of multidrug 
resistance protein 1 (MRP1) and inhibit transport of its conjugated organic anion 
substrates. In contrast, some of the flavonoids, markedly stimulate GSH transport by 
MRP1 (Ross and Kasum, 2002). In this study, the effects of twelve compounds at 
different concentration (0, 10, 50 and 100µM) were also been examined. The 
compounds used include apigenin, catechin, chrysene, curcumin, ellagic acid, emodin, 
epicatechin, genistein, kaempferol, luteolin, naringenin and quercetin. Seven of them 
have a concentration-dependent inhibition of GSH efflux mediated by MRP4 (Figure 
4.4A and B). The presence of 50 and 100µM curcumin led to a decrease in GSH 
efflux by 20.6% and 37.1% in MRP4/Hep G2 (Table 4.7). The presence of 50 and 
100µM ellagic acid led to a decrease in GSH efflux by 33.3% and 42.9% in 
MRP4/Hep G2 (Table 4.8).  The presence of 50 and 100µM kaempferol led to a 
decrease in GSH efflux by 19.4% and 22.6% (Table 4.9). The presence of 100µM 
luteolin led to a decrease in GSH efflux by 48.1% (Table 4.10). The presence of 
100µM apigenin led to a decrease in GSH efflux by 27.3% (Table 4.11). The presence 
of 10, 50 and 100µM quercetin led to a decrease in GSH efflux by 38.3%, 63.0% and 
64.2%, respectively (Table 4.12). The presence of 50 and 100µM genistein led to a 
decrease in GSH efflux by 14.8% and 23.5% (Table 4.13). These seven compounds 
had no effect on the total GSH levels in cells and corresponding increases in cellular 
GSH accumulation were also observed. No obvious effects on GSH export were 
observed with the other five compounds, which are epicatechin, narigenin, catechin, 
chrysene and emodin (Table 4.14).  Cell viability as determined by trypan blue 
staining was not affected in all of above experiments. 
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Table 4.7   Effect of curcumin on GSH efflux 
 
Cells were incubated in HBSS buffer containing 5.6mM glucose, 0.5mM acivicin and 
different concentration curcumin at 37。C for 10min. The difference between the 
efflux from MRP4/Hep G2 and that from v/Hep G2 cells represents the efflux 
mediated by MRP4. Values shown are expressed as means ± SD from three 
independent determinations. (*)Compared with the corresponding untreated cells, 




































0 (control) 54.2±1.1/ 15.6±0.4 24.3±0.7 8.4±0.8 
 55.3±1.2   [0%] 
     
10 53.6±0.8/ 15.0±0.7 22.4±0.7* 8.1±1.2 
 55.5±1.3   [3.6%] 
     
50 53.0±0.9/ 14.1±0.4* 20.0±0.6* 5.6±0.3* 
 54.5±0.6   [33.3%] 
     
100 54.3±1.0/ 13.6±0.2* 18.6±0.6* 4.8±0.4* 
































0 (control) 55.5±1.0/ 14.0±0.2 23.6±0.5 9.7±0.5 
 58.7±1.0   [0%] 
     
10 56.9±1.2/ 12.7±0.1* 22.4±0.4* 9.7±1.1 
 57.6±0.4   [0%] 
     
50 51.2±1.4/ 8.3±0.3* 15.9±0.3* 7.7±0.6* 
 53.4±0.9   [20.6%] 
     
100 51.5±1.3/ 6.2±0.4* 12.3±0.1* 6.1±0.8* 
 54.1±1.1   [37.1%] 
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0 (control) 53.3±1.2/ 15.2±0.5 23.8±0.9 8.1±0.9 
 54.3±1.4   [0%] 
     
10 52.8±1.5/ 15.0±0.7 22.6±0.4 7.7±0.4 
 52.5±1.4   [4.9%] 
     
50 53.6±1.2/ 14.3±0.2 22.1±0.6* 7.6±0.5 
 54.3±1.3   [6.2%] 
     
100 54.2±0.8/ 14.3±0.6 18.6±0.2* 4.2±0.5* 
































0 (control) 52.1±0.6/ 14.4±0.2 23.6±0.5 9.3±0.5 
 51.6±0.6   [0%] 
     
10 52.1±1.2/ 11.0±0.4* 20.1±0.4* 8.9±1.1 
 50.6±0.9   [4.3%] 
     
50 51.1±1.4/ 9.3±0.5* 17.3±0.3* 7.5±0.6* 
 53.7±1.0   [19.4%] 
     
100 57.6±1.2/ 8.6±0.8* 16.5±0.1* 7.2±0.8* 
 55.9±0.9   [22.6%] 
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0 (control) 48.5±1.2/ 14.1±0.9 23.0±0.5 8.8±0.7 
 51.7±0.3   [0%] 
     
10 49.4±1.5/ 14.1±0.9 22.2±0.6 8.5±1.1 
 52.8±0.7   [3.4%] 
     
50 48.1±1.2/ 11.0±0.5* 18.1±1.1* 7.0±0.6 
 50.2±1.3   [20.5%] 
     
100 49.5±1.5/ 9.0±0.2* 15.9±0.8* 6.4±0.8* 



































0 (control) 52.6±1.1/ 16.1±0.5 24.2±0.5 8.1±0.5 
 50.5±0.9   [0%] 
     
10 53.3±1.4/ 14.3±1.0 20.2±0.7* 5.0±1.7* 
 51.2±1.3   [38.3%] 
     
50 51.0±1.4/ 10.1±0.5* 13.1±0.4* 3.0±0.8* 
 50.1±1.2   [63.0%] 
     
100 54.2±0.8/ 9.1±0.3* 12.2±0.3* 2.9±0.6* 



































0 (control) 53.3±0.8/ 14.9±0.3 23.1±0.5 8.1±0.6 
 54.0±1.1   [0%] 
     
10 53.5±0.5/ 14.9±0.7 22.8±0.8 7.9±0.2 
 53.7±1.5   [2.5%] 
     
50 53.2±0.7/ 14.7±0.3 21.7±0.5* 6.9±0.3* 
 54.6±1.3   [14.8%] 
     
100 53.6±0.6/ 14.3±0.5 20.3±0.3* 6.2±0.5* 





Table 4.14     Compounds which did not have any effects on GSH efflux (data only 






























0 (control) 53.2±0.6/ 15.8±0.3 25.6±0.5 9.8±0.3 
 
55.5±1.2 
    
Catechin(100) 53.5±0.4/ 15.0±0.5 24.3±0.6 9.3±0.2 
 
53.5±0.8 
    
Chrysene(100) 53.6±1.0/ 15.1±0.6 24.4±0.4 9.4±0.8 
 
54.9±1.0 
    
Emodin(100) 52.1±0.3/ 14.8±0.4 24.3±0.2 9.6±0.2 
 
53.0±0.6 
    
Epicatechin(100) 51.4±1.1/ 13.5±1.3 22.7±1.4 9.3±0.3 
 
52.1±1.4 
    
Naringenin(100) 53.0±1.2/ 14.2±0.8 22.8±0.5 8.0±1.1 
 
54.5±1.0 


















































Figure 4.4   Effects of polyphenols on GSH efflux. Cells were incubated with HBSS 
containing 5.6 mM glucose, 0.5 mM acivicin and 0-100 µM compounds and 
incubated at 37。C for 10 min. (A) Effect of quercetin, luteolin, ellagic acid and 
curcumin on ABCC4-mediated export of GSH. (B) Effect of apigenin, kaempferol 
and genistein on ABCC4-mediated export of GSH. The open bars show the values in 
the absence or in the presence of quercetin or apigenin, the black bars show the values 
in the absence or in the presence of luteolin or kaempferol, the horizontal striped bars 
show the values in the absence or in the presence of ellagic acid or genistein and the 
dotted bars show the values in the absence or in the presence curcumin. Values shown 
are means ± SD of two independent experiments performed in triplicates. (*)  
Indicates P<0.05 (ANOVA analysis) when compared to the corresponding controls in 













 4.2.      Cloning and expression of mutant MRP4 
    4.2.1.     PCR 
Mutant MRP4 fragments were obtained by PCR using the full-length MRP4 cDNA in 
pcDNA6 vector as the template. In the first round of PCR, ten MRP4 fragments were 
generated as the templates for five mutant clones (Figure 4.5). Five mutant MRP4 
fragments were then obtained during the second round PCR (Figure 4.6).                
 
 
Figure 4.5   Template for mutant MRP4 fragments. Lanes 1 and 2 showed fragments 
(size 504bp and 702bp) as the template from clone R165K (original amino acid R 
mutated to K). Similarly, lanes 3 and 4 from clone R165N; lanes 5 and 6 (size 521bp 
and 682bp) from C171G; lanes 7 and 8 from R951M (size 484bp and 1139bp); lanes 





Figure 4.6   Mutant MRP4 fragments. Lanes 1-3 showed fragments for R165K, 
R165N, C171G clone (size 1184bp). Lanes 4-5 show fragments from the R951M and 
D953Q clones (size 1605bp).  
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4.2.2.   Cloning of mutant MRP4 into cloning vector 
The second round PCR products for clones R165K, R165N and C171G were cloned 
into pGEM-T vector and digested with the EcoRΙ and EcoRV (Figure 4.7). The 
1184bp fragments were then confirmed by sequencing and compared to the sequence 
of the wild-type MRP4 using BLAST program. The results showed that the sequences 
of all mutant clones were identical with the only exception of mutated nucleotides.  
 
The PCR fragments for clones R951M and D953Q were first cloned into pGEM-T 
vector. After confirming the sequences and mutations by digestion with HincΙΙ/ XhoΙ 
and sequencing, the 1605bp fragments were subcloned into MPR4/pBS (full-length 
MRP4 cDNA with no stop codon in pBlueScript vector). The restriction enzyme 
digestion and sequencing were repeated again. Figure 4.8 shows the sizes of the 




Figure 4.7   Restriction enzyme digestion of R165K, R165N and C171G clones by 
EcoRΙ and EcoRV in pGEM-T vector. Lane 1 showed R165K fragment (1184bp) and 
the pGEM-T vector (3.0kb). Similarly, lane 2 showed R165N fragment and the 
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(A)                                                                        (B) 
                                                     
 
Figure 4.8   Restriction enzyme digestion of R951M and D953Q clones with HincΙΙ 
and XhoΙ. (A) Lanes 1 and 2 showed R951M and D953Q fragment (1605bp) in 
pGEM-T vector (3.0kb). (B) Lanes 1 and 2 showed the same mutant MRP4 fragment 
(1605bp) in the full-length MPR4/pBS construct (7.0kb). 
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 4.2.3.     Construction of mutant full-length MPR4 expression 
plasmid 
The 1184bp EcoRΙ/EcoRV fragments (from clones R165K, R165N and C171G) and 
the 2795bp EcoRV/XhoΙ fragments (from clones R951M and D953Q) were subcloned 
to the MRP4/pcDNA6 construct to generate the recombinant pcDNA6-mutant MRP4. 
The full-length mutant MRP4 fragments were subjected to restriction enzyme 
digestion (Figure 4.9) and sequenced again (Figure 4.10). The results showed that the 
sequence is consistent with that in the pGEM-T vector. 
   
 
 
Figure 4.9   Restriction enzyme digestion of pcDNA6-mutant MRP4 vector by EcoRΙ 
and XhoΙ. Lanes 1-5 showed the mutant clones R165K, R165N, C171G, R951M and 
D953Q accordingly. The 3975bp band was from the mutant MRP4, and the 5.1kb 














   1         2          3                  4     5 
A 
 
Query: 421 cacttatatttttatcacgttcagtgtgctgggatgAAGttacgaggtagcccatgtgcc 480 
       ||||||||||||||||||||||||||||||||||||| |||||||||||||||||||||| 







Query: 421 cacttatatttttatcacgttcagtgtgctgggatgAACttacgaggtagcccatgtgcc 480 
       |||||||||||||||||||||||||||||||||||||  ||||||||||||||||||||| 






Query: 467 ttacgagtagccatgGGTcatatgatttatcggaaggcacttcgtcttagtaacatggcc 527 
 














Figure 4.10   DNA sequence of mutant pcDNA6-MRP4. A-E showed the blast results 
of nucleotides sequence for clones R165K, R165N, C171G, R951M and D953Q 
(“query” line) accordingly with published MRP4 cDNA sequence (GenBank access 
number AF071202) (“sbjct” line). The sequnce of mutated nucleotides is in bold and 
capital letters. 
 
    
          ||||||||||||||| | ||||||||||||||||||||||||||||||||||||||||||
Query: 344 tcttgtttttgacaacgtcccgctggttcgccgtcATGctggatgccatctgtgccatgt 403
           |||||||||||||||||||||||||||||||||||   ||||||||||||||||||||||
Sbjct: 2816tcttgtttttgacaacgtcccgctggttcgccgtcCGTctggatgccatctgtgccatgt 2875
Query: 344 tcttgtttttgacaacgtcccgctggttcgccgtccgtctgCAAgccatctgtgccatgt 403
Sbjct: 2816tcttgtttttgacaacgtcccgctggttcgccgtccgtctgGATgccatctgtgccatgt 2875
           ||||||||||||||||||||||||||||||||||||||||| | ||||||||||||||||
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 4.2.4.     Expression of mutant MRP4 protein in Hep G2 cells 
Mutant MRP4 proteins were stably transfected into Hep G2 cells and the resistant 
cells were selected with blasticidin. The wild-type MRP4 and the empty pcDNA6 
vector were also transfected as controls. The MRP4 ORF was cloned in frame with a 
V5 epitope and a polyhistidine sequence at the C-terminal. The predicted size of 
MRP4 is ~149kD and that with the V5 and polyhistidine sequence is ~153kD. A 
protein of about 150kD was detected in both mutant and wild-type MRP4/Hep G2 
cells but not in v/Hep G2 cells by using an anti-V5 antibody (Figure 4.11). Actin 
expression (42kD) was also detected by the anti-actin antibody to normalize the 
protein quantity in the experiment. Relative levels of protein expression were 
estimated by densitometric analysis and the ratio of wild-type and mutant MRP4 was 
calculated. The mutant clones with comparable expression level with wild-type MRP4 
were selected for further experiments. 
A  
 
lane 1 2 3 4 5 6 7 
name WT R165K R165N 
Ratio 
(MRP4/actin)
0.83 0.79 0.69 0.27 0.94 1.02 0.73 
Ratio 
(mutant/WT) 
1.00 0.95 0.83 0.32 1.13 1.23 0.88 
Selected clone  √   √   
 






lane 8 9 10 11 12 13 14 
name V C171G R951M 
Ratio 
(MRP4/actin) 
--- 0.76 0.82 0.99 0.97 0.93 0.71 
Ratio 
(mutant/WT) 
--- 0.92 0.99 1.19 1.17 1.12 0.85 














Selected clone  √  
 
 
Figure 4.11     Western blot analysis of wild-type and mutant MRP4 expression in 
Hep G2 cells. The numbers in the table below the blots referred to the relative 
expression level. (A) shows the R165K and R165N clones, (B) shows the C171G and 
R951M clones and (C) shows the D953Q clone. Wild-type MRP4 (WT) and empty 
pcDNA6 vector (V) served as the controls in this experiment. The clones selected for 
further analysis are indicated with tick marks.  
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        4.2.5.    Localization of mutant MRP4 in Hep G2 cells 
Immunostaining was performed to ensure that mutant MRP4 proteins were localized 
to the cell membrane. The antibody was specifical for the V5 epitope and was 
conjugated to FITC to stain the cells. The mounting solution containing propidium 
iodide was used to counterstain the cells to show the nucleic acids. Figure 4.12 shows 
that the MRP4 proteins were localized to the cell membrane.  
 
Vector   
       
 
Wide-type 
       
 
R165K 




       
C171G 
         
R951M 
     
D953Q 
   
Figure 4.12     Immunostaining of Hep G2 cells overexpressing wild-type and mutant 
MRP4.  MRP4 was detected by immunofluorescence with anti-V5 antibody (green 
signal) and nucleic acids were counterstained with propidium iodide (red signal). Both 
signals were superimposed to show the membrane localization of MRP4.  
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4.3.   Functional study of mutant MRP4 
Site-directed mutagenesis was carried out to examine the role of specific highly 
conserved amino acids of MRP4 on its transport activity.   
          4.3.1.       Cytotoxic assay 
Cytotoxic assay was carried out on stable transfected mutant MRP4/Hep G2 cells to 
examine the drug resistance profiles of the mutant MRP4 proteins. Empty pcDNA6 
vector transfected cells and wild type MRP4 transfected cells were used as the 
negative and positive control, respectively. In this study, we found that the IC50 values 
of mutant clones R165N and C171G for both drug 6-TG and 6-MP were similar to 
that of vector, while the IC50 values of clones R165K, R951M and D953Q were 
similar to that of wild type MRP4. This indicates that substitution of amino acid at 
position 165 and 171 in the putative first transmembrane segment of MRP4 protein 
with non-conserved amino acid residues resulted in the loss of drug resistance for 
some purine analogues. The IC50 values are shown in Table 4.15.  
Table 4.15   IC50 of resistance to drugs of mutant MRP4/Hep G2 cells. 
 
Cell line  
Vector WT-
MRP4 
R165K R165N C171G R951M D953Q
IC50(µM)  
6-TG 14.5±0.8 46.8±0.4 43.2±1.0 19.7±0.7 24.4±0.3 44.0±0.3 44.4±0.4
Fold 1.00 3.22 2.98 1.36 1.68 3.03 3.06 
IC50(µM) 
6-MP 57.0±0.4 84.5±0.4 80.3±0.5 60.6±0.7 66.4±0.3 87.6±0.5 85.8±0.5
Fold 1.00 1.48 1.41 1.06 1.16 1.54 1.51 
 
Cells were exposed to 6-TG or 6-MP for 48 hours. MTS reagent was added and cells 
were incubated for 60 minutes. The absorbance was measured at 490 nm. At least five 
drug concentrations were used to determine IC50 values (the concentration at which 
the cell growth is inhibited by 50%). Each concentration was carried out in two 
independent experiments performed in triplicates. The fold resistance is obtained by 
the ratio of IC50 of mutant or wild-type MRP4 cells to that of negative control vector 
cells.   
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4.3.2.   Export of bimane-GS of mutant MRP4/Hep G2 cells 
Export of bimane-GS was performed in mutant cells as described in section 4.1.1. 
Empty pcDNA6 vector transfected cells and wild-type MRP4 transfected cells were 
included as the negative and positive control, respectively. As shown in Table 4.16, 
the amount of bimane-GS synthesized by all clones was similar to that of controls. 
However, the efflux of bimane-GS of R165N and C171G clones was dramatically 
reduced and was similar to that of the empty vector-transfected clones (Figure 4.13), 
while the efflux of bimane-GS of R165K, R951M and D953Q clones was similar to 
that of wild type MRP4. These results indicate that substitution of Arg165 with Asn 
and substitution of Cys171 with Gly abolished the transport capacities of MRP4 protein 
for the substrate bimane-GS.  
 




Cell line Bimane-GS synthesis (nmol/mg protein/10min) 
Vector 48.0 ± 0.6 
WT-MRP4 48.9 ± 1.0 
R165K 49.5 ± 0.9 
R165N 50.6 ± 0.8 
C171G 49.8 ± 0.4 
R951M 49.8 ± 0.6 
D953Q 49.5 ± 1.0 
  
Cells were preincubated at 10。C with medium containing 100 µM of MCB. The 
medium was replaced with HBSS containing 5.6mM glucose and incubated at 37。C 
for 10min. Bimane-GS exported into the incubation buffer and intracellular bimane-
GS were measured and added to obtain the total bimane-GS synthesis. Results are 
expressed as means ± SD of triplicate determinations. The total bimane-GS synthesis 
of all clones was comparable to that of wild-type MRP4 and vector cells (ANOVA 




































Figure 4.13   Efflux of bimane-GS from mutant MRP4/Hep G2 cells and controls at 
10-min time point. Cells were preincubated at 10。C with medium containing 100 µM 
of MCB. The medium was removed and replaced with HBSS containing 5.6mM 
glucose and incubated at 37。C. Bimane-GS exported into the incubation buffer was 
measured at 10-min time point. The bimane-GS efflux from mutant MRP4/Hep G2 
and vector cells was compared to that from wild-type MRP4 cells and (*) indicated 
that the difference was significant (ANOVA analysis, p<0.05). Results are expressed 





4.3.3.    Export of reduced GSH of mutant MRP4/Hep G2 cells 
Export of GSH was performed in mutant cells as described in section 4.1.3. Empty 
pcDNA6 vector transfected cells and wild-type MRP4 transfected cells were included 
as the negative and positive control, respectively. As shown in Table 4.17, the amount 
of total GSH of all clones was similar to that of controls. However, the efflux of GSH 
of R165N clone was dramatically reduced and was similar to that of the empty vector-
transfected clones (Figure 4.14), while the efflux of GSH of other four mutant clones 
was similar to that of wile type MRP4. These results indicate that substitution of 
Arg165 with Asn abolished the transport capacities of MRP4 protein for GSH.  
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Table 4.17   Total GSH of mutant MRP4 and controls over a 10-min time course.  
 
 Cell line Total GSH (nmol/mg protein/10min) 
Vector 46.3 ± 1.0 
WT-MRP4 46.5 ± 1.2 
R165K 47.5 ± 0.3 
R165N 46.1 ± 0.9 
C171G 46.5 ± 1.3 
R951M 46.6 ± 0.5 
D953Q 47.2 ± 0.4 
 
Cells were incubated at 37。C with HBSS containing 5.6mM glucose and 0.5mM 
acivicin. GSH exported into the incubation buffer and intracellular GSH were 
measured at 10-min time point and added to obtain the total GSH. Results are 
expressed as means ± SD of triplicate determinations. The total GSH of all clones was 


































Figure 4.14   Efflux of GSH from mutant MRP4/Hep G2 cells and controls at 10-min 
time point. Cells were incubated at 37。C with HBSS containing 5.6mM glucose and 
0.5mM acivicin. GSH exported into the incubation buffer was measured at 10-min 
time point. The GSH efflux of mutant MRP4/Hep G2 and vector cells was compared 
to that of wild-type MRP4 cells and (*) indicated that the difference was significant 




5.   Discussion 
 
MRP4-mediated transport  
 
The first part of study was carried out to determine if flavonoids and plant 
polyphenols affect MRP4-mediated efflux of gluthathione and glutathione conjugates. 
The ability of MRP4 to confer resistance to therapeutic drugs and to transport 
endogenous and exogenous molecules had been the focus of study on MRP4 in the 
past few years. These studies had shown that MRP4 mediates resistance to purine 
analogs and other nucleoside-based antiviral drugs (Schuetz et al., 1999; Lee et al., 
2000). In addition, this transporter is also able to facilitate the efflux of cyclic 
nucleotides such as cAMP (Jedlitschky et al., 2000; Chen et al., 2001), p-
aminohippuric acid (Smeets et al., 2004), prostaglandins (Reid et al., 2003), bile salts 
(Zelcer et al., 2003), and various conjugated molecules. The latter includes 
conjugated bile salts, dehydroepiandrosterone 3-sulphate (Zelcer et al., 2003) and 
estradiol-17-β-D-glucuronide (Chen et al., 2001). Earlier studies in our lab had also 
shown that MRP4 mediates the efflux of the glutathione conjugate, bimane-
glutathione (Bai et al., 2004).  
In addition, increased efflux of GSH was also observed in cells overexpressing MRP4 
(Lai and Tan, 2002). Thus, MRP4 joins other members of the MRP family which 
have this capability. GSH has many important roles in the protection of cells from 
oxidative stress. For example, GSH is a reducing agent of hydrogen and lipid 
peroxides and also inactivates electrophilic compounds through spontaneous or GST 
catalysed formation of conjugates. The ratio of reduced GSH to glutathione disulphide 
(GSSG), the oxidized form of GSH, is a reflection of cellular homeostasis. Membrane 
vesicle and intact cell studies as well as data from knockout mice and mutant rats 
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indicate that MRP1 and MRP2 can transport GSH and GSSG (Leslie et al., 2001). In 
mrp1 (-/-) cells, the amount of GSH effluxed is only half of that of wild-type cells 
(Rappa et al., 1997). The calcium channels blocker verapamil, although not a 
substrate of MRP1, has been shown to remarkably increase MRP1’s affinity for GSH 
(Loe et al., 2000a). Several dithiane analogs of verapamil and several flavonoids are 
also able to stimulate GSH transport by MRP1 (Loe et al., 2000b; Leslie et al., 2001a). 
Early studies demonstrating that biliary GSH is markedly decreased in mrp2 deficient 
rats (Lu et al., 1996) suggested that MRP2 is capable of transporting GSH, either 
alone or together with other substrates (Paulusma et al., 1999). There is no evidence 
that MRP3 transport GSH (Kool et al., 1999b). Interestingly, MRP5 appears to 
transport GSH despite significant differences in primary structures from MRP1 and 
MRP2 (Wijnholes et al., 2000b; Jedlitschky et al., 2000). MRP4 which has a structure 
similarity to MRP5 can also transport GSH (Lai and Tan, 2002). 
 
Expression of MRP4 in human tissues 
MRP4 is expressed in many human tissues and organs. These include liver, prostate, 
lung, intestine, kidney, muscle, brain, pancreas, testis, ovary, adrenal gland, bladder 
and gallbladder (Rius et al., 2003). Drug absorption mainly happens in the 
gastrointestinal tract. The intestine is primarily regarded as an absorptive organ as 
well as an organ prepared for the elimination of certain organic acids. The interactions 
of drugs with intestinal membrane transporters have an important impact on the 
intestinal drug absorption and secretion (Kunta and Sinko, 2004). MRP4 is expressed 
in the intestinal tract, including duodenum, jejunum and ileum (Prime-Chapman et al., 
2004; Zimmermann et al., 2004). Thus, it is posssible that MRP4 may play a role in 
intestinal drug efflux (Taipalensuu et al., 2001).  
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The liver plays a key role in the clearance and excretion of many drugs and 
hepatobiliary system is a main route for drugs and their metabolites to leave the body 
(van Montfoort et al., 2003). Many transporters are present on the canalicular 
membrane to mediate the process of hepatobiliary excretion of drugs. Previous studies 
have demonstrated that MRP4 is localized to the basolateral membrane of human 
hepatocytes and human hepatoma Hep G2 cells. MRP4 can mediate the release of 
GSH into the extracellular space and has been shown to function as an ATP-
dependent cotransporter of GSH together with monoanionic bile salts (Rius et al., 
2003; Lai and Tan, 2002).  
 
Effects of flavonoids and plant polyphenols on ABC 
transporters 
 
Flavonoids and plant polyphenolic compounds are present in our food and drinks 
(mainly in vegetables, fruits, tea and wines). In addition, some of these compounds 
are also often taken as health supplements or as alternative or complementary therapy 
for cancer. Thus, it has been estimated that milligrams to even grams quantities of 
these compounds may be consumed daily by an individual. Plant polyphenols have 
been shown to influence the activity of drug metabolism enzymes as well as 
transporters. There had been reports documenting the effects of plant polyphenols on 
ABC transporters including that on P-gp, MRP1, CFTR and BCRP (ABCG2). With 
regards to MRP proteins, most of the studies had been carried out for MRP1 and to a 
lesser extent for MRP2. Several flavonoids have been observed to inhibit the transport 
of LTC4 and E217βG by MRP1 (Leslie et al., 2001a). Moreover, some flavonoids (e.g. 
kaempferol, naringenin, genistein, flavopiridol and apigenin) are able to mildly 
stimulate the ATPase activity of MRP1, suggesting that these may be substrates of the 
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transporter (Leslie et al., 2001a; Hooijberg et al., 2000). Genistein, kaempferol and 
apigenin increased daunorubicin accumulation in a MRP1 overexpressing lung cell 
line (Hooijberg et al., 1999b). It has also been reported that MRP2 also transports 
flavonoids and their conjugated metabolites (Walgren et al., 2000; Walle et al., 1999).  
 
Effects of flavonoids and plant polyphenols on MRP4 
The expression of MRP4 in the liver and intestine and the previous observations that 
ABC transporters can be influenced by dietary flavonoids and plant polyphenols had 
prompted us to examine if this is also true for MRP4. To achieve this, we examined 
the effects on GSH and bimane-gluthathione transport in Hep G2 cells stably 
expressing MRP4 (MRP4/Hep G2). Hep G2 cells transfected with the empty vector 
(v/Hep G2) served as the controls.  
 
Under the experimental conditions used in this study, detectable efflux of GSH and 
bimane-glutathione were observed in control v/Hep G2 cells. This is probably 
facilitated by MRP proteins that are endogenously expressed in Hep G2 cells (Lee et 
al., 2001; Roelofsen et al., 1997). However, consistent with the previous studies in 
our lab, it was observed that cells stably expressing MRP4 were able to significantly 
enhance the efflux of GSH as well as bimane-glutathione.  
 
Under the experimental conditions employed for this study, it was observed that the 
flavonoids and plant polyphenols used did not affect the total GSH synthesis (Tables 
4.7-4.14), although Myhrstad et al had shown that flavonoids are able to induce the 
expression of γ-glutamylcysteinyl synthetase, which catalyses the rate-limiting step 
for GSH synthesis (Myhrstad et al., 2002). There are two possible explanations for 
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this. Firstly, it may be possible that in this study, the short duration of the exposure to 
the flavonoids was not sufficient for the induction to be observed. Secondly, some 
polyphenolic flavonoids such as quercetin and kaempferol, have a number of 
hydroxyl groups display pro-oxidant activities (Sahu and Gray, 1996). An antioxidant 
defense system consisting of GSH (Bellomo et al., 1992) and glutathione S-
transferase (GST) (Tan et al., 1988) is present in the cell to protect the cell from lipid 
peroxidation and DNA strand breaks by reactive oxygen species generated during the 
auto-oxidation and redox cycling of the flavonoids (Sahu and Gray, 1993, 1994; Sahu 
and Washington, 1991). Depletion of GSH by the flavonoids can lead to oxidative 
stress (Sahu and Gray, 1996). However, several flavonoids including apigenin and 
quercetin have been shown to induce the expression of γ-glutamylcysteinyl synthetase, 
the rate limiting enzyme for GSH biosynthesis (Myhrstad et al., 2002). Thus, although 
flavonoids could cause a decrease in cellular GSH pools through the oxidative stress, 
this may be balanced, at least in part, by a flavonoid-induced increase in GSH 
biosynthesis.  
 
Of the twelve compounds used in this study, seven of them had varying degree of 
inhibitory effect on GSH efflux. At 100µM, the order of inhibitory effects was: 
quercetin> luteolin > ellagic acid > curcumin > apigenin > genistein / kaempferol. An 
earlier study with another member of the MRP family, MRP1, showed that four 
bioflavonoids, namely; apigenin, naringenin, genistein and quercetin at a 
concentration of 30µM, stimulated the GSH transport in inside-out MRP1-enriched 
membrane vesicles (Leslie et al., 2003). It is unclear why the effects on MRP1 are 
different from that on MRP4. It may be due to a difference in experimental procedure 
whereby inside-out membrane vesicles were used in the study by Leslie et al, while 
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intact cells used in our study. In addition, MRP1 has an additional membrane 
spanning domain which is not present in MRP4 and this difference in the structures of 
MRP1 and MRP4 may contribute to this difference in observations.  
 
The effect of the flavonoids and plant polyphenols on bimane-glutathione synthesis 
was also examined. There was no significant change to the total bimane-glutathione 
indicating that there was no inhibition in the glutathione-S-transferase (GST) reaction 
that is needed to generate the bimane-glutathione conjugate. This observation was 
rather surprising as it was previously shown that quercetin was effective in inhibiting 
the formation and efflux of bimane-glutathione from the colon adenocarcinoma cell 
line, COLO 320HSR (Zhang and Wong, 1997). In our study, quercetin had no effect 
on the formation as well as the efflux at concentration up to 100µM. It is tempting to 
speculate that the difference may be due to the efflux of quercetin glucoside by MRP2 
transporters expressed in Hep G2 cells thereby reducing the net uptake of quercetin by 
the cells. However, this may not be the case as quercetin was observed to be effective 
in reducing GSH efflux.  
 
However, five of the compounds tested did significantly reduce the efflux of bimane-
glutathione. At 100µM, the order of inhibitory effects was: curcumin > kaempferol > 
luteolin/ apigenin > ellagic acid. Inhibition of MRP1 mediated transport of 
leukotriene C4 and estradiol-17-β-D-glucuronide by dietary flavonoids had been 
previously described. Kinetic analysis showed that the flavonoids including 
kaempferol, apigenin, quercetin and naringenin were competitive inhibitors of 
leukotriene C4 transport (Leslie et al., 2001). Given the fact that flavonoids are 
substrates for both Phase I and Phase II reactions, it is possible that some of the 
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metabolites of the flavonoids may be conjugated and are substrates of MRP 
transporters.  
 
It was also postulated that some degree of hydrophobicity was required for the 
flavonoids to interact with MRP1 in its membrane environment (Leslie et al., 2001a). 
However, from our results, it seems that hydrophobicity dose not play a key role for 
flavonoids to interact with MRP4. For example, the flavone apigenin and the 
flavanone naringenin are structurally very similar to one another, differing by only 
one carbon-carbon double bond in the C-ring, and yet apigenin shows inhibition effect 
on both GSH and bimane-GS transport mediated by MRP4, while naringenin does not. 
In general, there was no observed structure-function relationship. For example, 
kaempferol was effective in inhibiting bimane-gluthathione efflux but another 
flavanol, quercetin had no inhibitory effect at all. In addition, the extent of inhibition 
of MRP4-mediated GSH efflux by plant polyphenols differs from the inhibition of 
bimane-glutathione efflux.   
 
Although all flavonoids have the same flavan nucleus in their structures, this study 
shows that the effects of flavonoids on MRP4 activity are rather varied and thus each 
flavonoid should be considered individually rather than as a single class of 
compounds. Our study shows that flavonols and flavones are inhibitors of GSH and 
bimane-glutathione efflux while the other classes of flavonoids do not appear to have 
any effects. In addition, other plant phenolic compounds such as curcumin and ellagic 
acid are also modulators of MRP4 activity. It had been previously suggested that 
certain flavoniods are promising potential modulators of multidrug resistance 
mediated by ABC transporters (Di Pietro et al., 2002). In this study, certain 
 113
flavoniods are able to inhibit MRP4-mediate efflux processes. However, care has 
been taken as flavoniods can also serve as substrates or modulate the activities of 
many drug metabolizing enzymes. 
 
Mutation analysis            
MRP4 functions as an ATP-driven export pump. Substrates of MRP4 include 
methotrexate, cAMP and cGMP, metabolites of chemotherapeutic agents, glutathione-
conjugated and glucuronide-conjugated organic anions (Chen et al., 2001; Lai and 
Tan, 2002). In addition, intracellular glutathione is also a substrate of MRP4 
(Wijnholds et al., 2000b; Lai and Tan, 2002). Although these substrates are 
structurally diverse, there still exists competition inhibition in transport between 
certain substrates of MRP4, such as inhibition of bimane-GS efflux by methotrexate. 
Earlier studies have shown that the predicted topology structure of MRP4 contained 
two membrane-spanning domains, each of which containing six transmembrane 
segments. The mechanism of how MRP4 transport the substrates is yet to be 
established. In the case of P-gp, predicted transmembrane (TM) regions appeared to 
be very important for its function because the sites for interaction with substrates are 
embedded in lipid bilayer (Ryu et al., 2000). Thus, as a step toward determining the 
substrate-binding sites of MRP4, site-directed mutagenesis of highly conserved 
residues were carried out on the basis of the alignment of the protein sequences of 
MRP family.  
 
Our results of western blotting showed that the expression level of all these five 
mutant clones was not affected and was comparable to that of wild-type MRP4. In 
addition, the pattern of immunostaining of these mutants was not changed when 
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compared with wild-type MRP4. These indicate that neutral and same-charged 
substitutions did not adversely affect MRP4 biogenesis.   
 
Role of Arg165 and Arg951         
Arg165 and Arg951 are predicted to be in the second transmembrane segment (TM2) 
and the eleventh transmembrane segment (TM11) of MRP4. Both arginine residues 
are extremely well conserved among MRP subfamily members. Arg165 is conserved 
with MRP1, -5 and -6, while Arg951 conserved with MRP1, -2, -5, -7 and -8 (Figure 
1.6).  
 
To examine the transport activity and the drug resistance phenotype of the R165K, 
R165N and R951M mutants, stably transfected human Hep G2 cells were generated. 
Our results showed that bimane-GS transport by the non-conserved substitution clone 
(R165N) was decreased significantly and similar to that from negative control vector-
transfected cells. However, the transport of bimane-GS by conserved substitution 
clone (R165K) and uncharged non-conserved substitution clone (R951M) was not 
affected and comparable to that of wild-type MRP4. The same results were obtained 
in GSH transport assay. In addition to the loss of bimane-GS and GSH transport 
activity, the R165N mutant clone can no longer confer resistance to the 
chemotherapeutic agents, including 6-TG and 6-MP, while the drug resistance profile 
appeared unchanged in the R165K and R951M clones.   
 
The substitution of Arg165 with conserved same-charged amino acid residue Lys (K), 
which is present in the corresponding position in MRP2 and MRP3, did not affect the 
transport activity of MRP4 or the resistance to 6-TG and 6-MP. However, the 
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replacement of Arg165 with non-conserved uncharged amino acid residue Asn (N) 
resulted in the loss of transport activity as well as the resistance to 6-TG and 6-MP. 
These facts suggest that this residue play an essential role in maintaining MRP4 in a 
transport state, especially its positively charged and well conserved properties. 
According to the fact that MRP4 is involved in transport of anionic conjugates, it is 
possible that positively charged amino acid residues in transmembrane helices are 
important in anionic substrate binding and transporting of MRP4. These findings were 
expected since same-charged mutations of basic amino acid residues have generally 
been reported to retain substrate binding and transport activities of MRP1 (Haimeur et 
al., 2002; Zhang et al., 2003). 
 
Replacing Arg951 with the hydrophobic neutral amino acid Met (M), the transport 
activity and drug resistance were similar to that of wild-type MRP4. This suggests 
that the positive charge of this residue Arg951 is not essential for substrate binding and 
transport by MRP4. This is consistent with a recent report that a neutrally substituted 
mutant of TM16 Arg1202 (R1202G and R1202L), which is the analogous residue in 
human MRP1, exhibited similar transport activities to those of wild-type MRP1 (Situ 
et al., 2004). It is also consistent with a result that neutrally substituted Arg1202 mutant 
(R1202G) could still transport LTC4 (Ren et al., 2003). However, interestingly, when 
the analogous residue in human MRP2 (Arg1210) was mutated to Ala, its ability to 
mediate cellular efflux of a fluorescent GSH conjugate was substantially reduced 
(Ryu et al., 2000). Whether or not this reflects a different role for this Arg residue in 




Role of Asp953   
Asp953 is predicted to be in the eleventh transmembrane segment (TM11) of MRP4. 
This aspartic acid amino acid residue is also present in MRP5. All the other MRPs 
also have an acidic amino acid residue, glutamic acid (E) in the corresponding 
position (Figure 1.6). The transport activity as well as the drug resistance to 6-TG and 
6-MP by uncharged substitution clone (D953Q) was not changed with that by wild-
type MRP4. However, it predicts that the residue Glu1204 in MRP1, corresponding to 
the position of residue Asp953 in MRP4, may face in towards a cavity that has been 
proposed as the substrate translocation pathway of MRP1 (Campbell et al., 2004). 
Thus, this residue would be well positioned to participate in hydrogen-bonding and 
other electrostatic interactions with polar and/or ionizable residues in other nearby 
TM helices and possibly directly with MRP1 substrates as well (Stenham et al., 2003; 
Dawson et al., 2003; Adamian and Liang, 2002, 2001). Interestingly, previous studies 
showed that transport of organic anions by neutrally substituted Glu1204 mutant 
(E1204L) of MRP1 was reduced or eliminated with the exception of MTX. These 
findings suggested that the Glu1204 side-chain is critical for establishing interhelical 
hydrogen bonding or ion pair interactions that are important for substrate transport of 
MRP1 (Situ et al., 2004).  
 
In our studies, although this substitution resulted in the loss of negatively charged and 
acidic properties, the transport activities and drug resistance by D953Q mutant clone 
were not changed compared to that of wild-type MRP4, indicating that this site may 




Role of SNP Cys171Gly in MRP4 
Single nucleotide polymorphisms (SNPs) are an abundant form of genome variation, 
distinguished from rare variations by a requirement for the least abundant allele to 
have a frequency of 1% or more (Brookes, 1999). The genomic sequence is 
approximately 99.9% identical from one individual to the next. It is this 0.1% 
difference that confers a unique phenotype to each individual. In addition to being 
responsible for phenotypic variation, this "minor" variation among individuals can 
also promote susceptibility to diseases. Many scientists are now beginning to associate 
disease risk with single nucleotide polymorphisms (SNPs) (Webb, 2002).  
Transporter proteins are important determinants in drug absorption, tissue targeting 
and elimination and play a role in the resistance of malignant cells to anticancer 
agents. Thus, the expression levels of these proteins in humans have important 
consequences for an individual’s susceptibility to certain drug-induced side effects, 
interactions, and treatment efficacy (Sparreboom et al., 2003). In addition to 
physiological and environmental factors, the expression and function of these proteins 
are modified by genetic polymorphisms (Eichelbaum et al., 2004). DNAs from 48 
Japanese individuals were screen by Saito et al for SNPs in eight genes encoding the 
MRP subfamily. Among these eight genes, 688 SNPs were identified, of which 230 
SNPs are in MRP4/ABCC4. Three SNPs in MRP4 are present in the transmembrane 
domain, including Cys171Gly, which may influence the function of the gene products 
and could have phenotypic consequences (Saito et al., 2002). 
Our results showed that transport of bimane-GS was significantly reduced by C171G 
mutant and similar to that of negative control vector-transfected cells. Similar 
reductions in the resistance to 6-TG and 6-MP were also observed. However, GSH 
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transport was not affected and was comparable to that of wild-type MRP4. This may 
be because the substitution of Cys171 by Gly results in the disruption of disulfide 
group between Cys171 and nearby amino acid residue Cys161 in MRP4. It thus implies 
that the formation of disulfide group in this position is important in the substrate 
binding and transport with the exception of GSH. Thus, SNP Cys171Gly appears to 
influence the transport activities and drug resistance of MRP4.  
Research into SNP variants is still in its early stages, and there are many challenges to 
be overcome. We should increasingly move toward learning to see and understand 





This study confirmed that as one of the ABC transporters, MRP4 can indeed facilitate 
the ATP-dependent efflux of the glutathione conjugate, bimane-glutathione. The 
transport of bimane-glutathione can be modulated by certain dietary plant polyphenols, 
including ellagic acid, curcumin, and the flavonoids apigenin, kaempferol and luteolin. 
 
This study also confirmed that MRP4 is able to facilitate glutathione efflux. The 
efflux can be also be modulated by dietary plant polyphenols and flavonoids, 
including ellagic acid, curcumin, apigenin, kaempferol, luteolin, genistein and 
quercetin. 
 
In addition, our study demonstrated that charged amino acid residue Arg165, located in 
the second TM of MSD1 as well as the SNP Cys171Gly are important determinants 
for MRP4-mediated transport and drug resistance. However, because of the limited 
mutation analysis and SNPs studied, it is difficult to fully determine structural and 
functional mechanism of the transport and drug resistance mediated by MRP4. It 
remains to be determined if other conserved charged amino acid residues and 
aromatic amino acid residues in other transmembrane helixes of MRP4 are indeed 
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